Stanislaw Rajmund Burzynski, Stanislaw R. Burzynski, Stanislaw Burzynski, Stan R. Burzynski, Stan Burzynski, S. R. BURZYNSKI, S. Burzynski, Arthur Burzynski, Hippocrates Hypocrite Hypocrites Critic Critics Critical HipoCritical
—————————————————————— Pat Clarkson, and I come from Danville, California, which is near San Francisco, and I have multiple myeloma; which is not a common cancer
About 20,000 people in the United States have the disease, and about 10,000 die every year, and 10,000 get the disease
So it’s a relatively small number of folks,that have it
So it’s not well
It’s not as well researched as some of the other cancers, um, but we’re hoping that the, um, Burzynski Clinic can help me
There’s not much hope for me
I, I have probably, a, uh, prognosis of a couple, couple years
Maybe a year or two to live, um, without, um, without I, I, an alternative method of treatment, and that’s why
——————————————————————
If I could say this a little differently
The conventional medicine, or what we would call conventional medicine, which is, you know, chemotherapy, radiation, uh, surgery; which is not possible with, uh, multiple myeloma because there is no, no large tumor that can be surgically removed, uh, the doctors have told us basically there is no cure, and that, and I, I say doctors; this is our local oncologist, um, and the head of oncology at, um, University of California, San Francisco; which is a very well respected school, uh, hospital, that there is no, uh, no reasonable possibility of a cure
Um, by contrast, uh, Dr. Burzynski, we have found out, has, uh, cured several people with myeloma, and he’s cured many other people with different kinds of cancer
The problem is, uh, that the FDA in its wisdom, will not allow us to, uh, be treated with the, uh, antineoplastons that are the backbone of the Burzynski therapy
——————————————————————
Well they’ve told us that they don’t have evidence that it’s, um, that it’s an effective treatment
Uh, that, they don’t have evidence that it’s not, non-toxic; which in fact, uh, is incorrect because the FDA does have evidence that it’s non-toxic
——————————————————————
Through the Senator’s office at the, the FDA is saying that they, they don’t know for sure that it’s not toxic; that’s not true, uh, and they don’t know that it will cure the disease, and therefor they can’t approve it
We’re willing
Pat’s willing to take the odds of a treatment, that is not 100% guaranteed, and let’s face it, most of the treatments that are approved by the FDA, are toxic, and are not guaranteed
So we don’t really understand, uh, why they have an issue with it, except that, uh, there’s an awful lot of money involved
Um, one of the peculiarities of the FDA, we understand they’re, by law, required to get much of their funding from the very companies that they’re supposed to be supervising
As, as I understand, uh, the Constitution, there is no basis in the Constitution for the Federal Government to be telling, an American, who they can use for a doctor or what drugs that they can use for, uh, their, their illness
Yet, over the years this, uh, this power has grown and been accepted at the FDA, and now it’s a, uh, uh, it’s, it’s out of control
——————————————————————
We have asked the FDA what is different about my case
Why I don’t get an exemption
We don’t have a response yet to that, to that question
——————————————————————
While doctors are generally very bright; they have to be to get through medical school, but they don’t have any training in critical, critical thinking, and most of them that I run into are not particularly good critical thinkers
The world they live in is to memorize a set of symptoms, then to look up or remember what those symptoms suggest in terms of a disease, and then remember or look up what the treatment is
So, here we have, um, uh, Dr. Burzynski, who is also a Ph.Dbiochemist, which is a, a interesting and, and very useful, uh, combination, who discovered that, um, in people who have cancer, they generally don’t have, or they have very reduced levels of what he now calls, uh, antineoplastons, and neoplaston is simply the medical jargon for cancer; so it’s anti-cancer, in effect, um, he discover the people who, uh, don’t have cancer, do have, high levels of this, and determined from research that these are controlled by, um, by the genes, and it’s part of the body’s immune system, in effect
We all produce cancer cells everyday of our lives
Like we produce bac, or have bacteria in our gi, digestive tract, that is controlled, by certain genes
In this case, um, he discovered that by, uh, by injecting, uh, or infusing, uh, these, they’re called peptides, peptide, that the patient could be helped
How, how innocuous, or how anti-toxic, can you have
It’s a, it’s a substance th, the body itself produces, unless the genes have shut down
Which is the case in, uh, some, in most, or at least half I guess, of multiple myeloma cases
——————————————————————
My, my message would be that they don’t have the right to tell me to hold a, a life or a death, um, decision
They, they don’t have the right to tell me that, um, I can’t have treatment that I seek, or I will die
I don’t think they have that right to do that
——————————————————————
Treatment is available
Uh, it is our choice
We are free Americans
We’re well informed
Uh, well educated
It should be our choice, and the Federal government in any, in any form should not have the authority to interfere with that
——————————————————————
Uh, nothing’s guaranteed in this world, um, but we’ve got, um, we’ve got some confidence in this clinic and in this treatment
======================================
Pat & Steve Clarkson
January 27, 2012
Houston, Texas
6:25
2/3/2012
——————————————————————
David H. Gorski, M.D., Ph.D., F.A.C.S. is an academic (i.e.: egg-head, paper-pusher, apparatchik) surgical oncologistspecializing in breast surgery and oncologic surgery
Gorski is no H.G. Wells
Wellscould, at least, tell a convincing lie; as he did in War of the Worlds
Gorski’d likely #fail as his evil half-brother, “H.G. #Fails”, in World War Peed, and probably didn’t think his readers would get the double-entendre’
Gorski is more famouser for pie in the sky
He’ll never be likened to Samuel Langhorne Clemens, or receive a “Mark Twain Award”
He’s an unlicensed Hackademic Quackademic who believes that bad press is good press, any press is good press
Gorski is the “Guy” who felt he was Scroogled by Google, when he and his public relations (P.R.) team; which reside in the hyperthalamus section of his brain, decided on 12/5/2012 to go pure pseudononsense pseudononscience:
Critiquing: Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies [1]
wherein he quoted
Dr Burzynski:
“I published the review article in a peer-reviewed journal almost 20 years ago on the principles of personalized gene-targeted therapy”
====================================== Gorski:
“Curious as to just what the heck Burzynski was talking about here, I searched PubMed for this alleged review article”
“I couldn’t find it on PubMed”
“His only publications from the 1990s had nothing to do with cancer as a “genetic disease” or “personalized gene-targeted cancer therapy” and everything to do with antineoplastons”
“Perhaps Burzynski proposed this “revolutionary”
new idea in a peer-reviewed article that’s not indexed in PubMed, but if he did I couldn’t find it using Google and Google Scholar”
“I was in graduate school 20 years ago, and was taught back then that cancer was primarily a genetic disease.. ”
“There’s a term called “oncogene,” which describes genes that, when either mutated or too much is made, can result in cancer” ======================================
====================================== Gorski would have the reader suspend belief, and believe that he’s notsmarter than a fifth-grader; which is entirely plausible
That he could not do a search on the words:
antineoplastons
oncogenes
Burzynski
and find anything whatsoever ======================================
======================================
and that he did not have the cranial capacity to access the Burzynski Clinic web-site’s Scientific Publications page: ======================================
======================================
The United States Food and Drug Administration(FDA) did NOT have any problem finding it ======================================
====================================== Pg. 24
1997 – Burzynski. S.R. Antineoplastons. oncogenes and cancer. Anti-Aging Medical Therapeutics, Vol.1. Klatz RM.
Goldman R. (Ed). Health Quest Publication 1997; Marina del Rey, CA. USA
——————————————————————
======================================
This, from a doctor, eager to prove to the world, just how smart he is, because of:
—————————————————————— 12/.5/2011 – “positions I hold at an NCI-designated comprehensive cancer center“[2] ======================================
====================================== 12/13/2012 – “positions I hold at an NCI-designated comprehensive cancer center“[3] ======================================
====================================== 3/7/2013 – “my last two jobs have been at NCI-designated comprehensive cancer centers“[4] ======================================
====================================== 11/2/2012 – “Personally having pored over Burzynski’s publications” [5] ======================================
====================================== 2/18/2013 – “I’ve read many of Burzynski’s papers” [6] ======================================
====================================== 6/5/2013 – “I do know cancer science” [8] ======================================
====================================== 6/10/2013 – “I do know cancer science” [9] ======================================
====================================== 6/7/2013 – “Unlike Mr. Merola, I am indeed very concerned with getting my facts correct” [10] ======================================
======================================
The same “Guy” who claimed:
Burzynskinever explains which genes are targeted by antineoplastons ======================================
======================================
A statement which I showed to be incorrect, by pointing out at least 18 different Burzynskiscientific publications which did what Gorski claimed they did NOT [11-12] ======================================
======================================
When Dr. David H. Gorski said:
—————————————————————— “Personally having pored over Burzynski’s publications”–11/2/2012
“I’ve read many of Burzynski’s papers”–2/18/2013
“I’ve searched Burzynski’s publications”–5/8/2013
——————————————————————
exactly what did he mean by “pored over,” “read,” and “searched”?
Some Bill Clintonesque definition designed to try and stump anyone who’s not smarter than a fifth-grader ?
(“It depends upon what the meaning of the word ‘is,’ is”)
You don’t have to be smarter than a fifth-grader to understand that ifDr. Gorski actually did what he said he did, that he should have been able to conclude without any hint of doubt, thatBurzynskiexplains which genes are targeted by antineoplastons
Where was your head ?
Was your head in Mississippi?
Was your head like a hole ?
Or was your head so far up your “Show Me State” pal Robert J.(don’t call me “Bobby”)Bob (I’m not a doctor, I just pretend like I’m one on the otherburzynskipatientgroup (TOBPG) and houstoncancerquack) blatherskite Blatherskitewicz(known liar) Blaskiewicz’s AstroTurf campaign, that you couldn’t see what you were not doing ?
This is a guywho has been funded by:
a) the Department of Defense(DOD)
b) the NIH (National Institutes of Health)
c) the Conquer Cancer Foundation of ASCO
and
d) the Robert Wood Johnson Foundation
and this is the kind of supposed “Science-Based Medicine”(SBM)“results” he produces ?
This guy is proclaimed as:
“a prolific essayist and managing editor of Science-Based Medicine, a highly-respected blog that exposes non-scientific research and practices”
A “highly-respected blog”?
really ?
Really ??
REALLY ???
You’ve gotta be kiddin’ me !!!
“For the last ten years, he has been a major voice — as himself and pseudonymously — for science-based medicine”
You mean that “Orac”Hack ?
“Dr Gorski also runs an active research laboratory at the Barbara Ann Karmanos Cancer Institute”
Research ?
Is it similar to his “research” which I exposed here?
And yet, after showcasing such “brillianot” research skilz, Tuesday, 7/30/2013, Dr. Gorski was appointed / named program co-director of Michigan Breast Oncology Quality Initiative(MiBOQI); a state-wide initiative to improve the quality of breast cancer care using evidence-based guidelines[13]
He “will be involved in many aspects of the quality initiative”
Let’s hope that one of those aspects is NOT the “research” one
“Dr. Gorski has the breadth and depth of knowledge to effectively lead our very strong Breast Multidisciplinary Team,” said Dr. Bepler
“I have every confidence that Dr. Gorski will continue this very high standard of care.”
Perhaps Dr. Bepler is out-of-touch with reality when it comes to Gorski’s “research” and “standard of care” abilities
I wonder how long it is before his effort at infiltrating evidence-based guidelines with his Science-Based Medicine, raises its ugly hypocritical head ?
During the Holidays, maybe Dr. Gorski will have time to celebrate his promotion with his wife with an evening out, and before he pops the surprise to her about his retirement plans for Castro’s Cuba, he can take her by the hands, stare into her eyes with his big brown eyes; they have to be brown, right (?), because he’s so full of “it,” (?) and tell her these heart-warming words:
Darling, I know, that you know, that what I do brings home the bacon, and so it makes a difference in Michigan
In fact, I wanted to let you know how much of a difference I’m helping to make
1997 thru 2001, African American women breast cancer death rates per 100,000 in Michigan; as reported in the American Cancer Society Cancer Facts & Figures for African Americans, 2005-2006, listed Michigan as the state tied with the 20 most breast cancer cases per 100,000, with 36.2
I’m proud to announce that for the last 2 reporting periods (2011-2014), covering 2003 thru 2009, Michigan is no longer tied with the state with the 20 most cases of breast cancer per 100,000
Michiganis now the state with the 11th most cases of breast cancer in African American women, which rose .5 from 33.8 to 34.3 over the last 2 reporting periods
And that’s not all
African American womenbreast cancer incidences inMichigan, per 100,000, rose from 119.0, 2000 thru 2004 as reported in the 2007-2008 report, up .4 to 119.4, 2006 thru 2010, as reported 2013-2014
Additionally, African American womenbreast cancer death rates inMichigan, per 100,000, rose from 33.8 for 2003 thru 2007, as reported for 2011-2012, up .5 to 34.3 for 2006 thru 2010, reported 2013-2014
And furthermore, breast cancer incidences in Michigan, per 100,000, were 119.4 for African American women for 2006 thru 2010, reported 2013-2014, and 118.7 for 2006 thru 2010 for white women, reported 2013-2014
So African American womenhad .7 more breast cancer incidences thanwhite women
And also, the breast cancer death rates inMichigan, per 100,000, was 34.3 forAfrican American women 2006 thru 2010, reported 2013-2014, 11.5 more than the 22.8 for white women for 2006 thru 2010, as reported 2013-2014
And I thought you’d be very pleased to know that the estimated new breast cancer cases in women inMichigan, rose from 6,120 in 2008, to 8,140 in 2013
An increase of 2,010
And, Michiganwent from being the state with the 9th most cases of estimated new breast cancer cases, to the 8th
And as if that were not enough great news for you, the estimated breast cancer deaths in women inMichigan, rose from 1,350 in 2004, to an additional 10 more women, 1,360 in 2013
And just like with the estimated new women breast cancer cases, again, Michiganwent from being the state with the 9th most cases of estimated breast cancer deaths, to the 8th
And last, but certainly not least, Michigan cancer death rates dropped from 25.8 in 2008, 1.8 to 24.0 in 2013
However, Michiganwent from being the state tied with the 18th most cancer cases per 100,000, to the state tied with the 11th most
But don’t worry honey
If you’re white like me, because you’re in Michigan, the breast cancer incidence for you per 100,000, went from 133.9 for 1998 thru 2002, as reported 2005-2006, down 15.2 to 118.7 for 2006 thru 2010, as reported 2013-2014
And, even better, white death rates in Michigan per 100,000, dropped from 27.3 for 1996 thru 2000, as reported 2003-2004, 4.5 to 22.8 for 2006 thru 2010, as reported 2013-2014
And best of all, sweetie, if you do get breast cancer and you’re white, you have a 9% better 5-year overall survival rate (69% – whites / 60% – African Americans, and for each stage of diagnosis for most cancer sites)
And I’d be remiss if I didn’t point out that life expectancy is lower forAfrican Americans than whites among women (77.2 vs. 80.9 years) (2013-2014)
If that’s not job security for me, I don’t know what is
The mistake that Gorski made is that he did not take into account that this is not the age of Hitler, Stalin, Lenin, Mussolini, etc
In this day and age, people canNOT get away with adopting lying as a part of a strategy, because the NSA is watching, and so are We, the People
Remain calm
Germans subjugated themselves to Hitler, the Soviets, Stalin, Italians, Mussolini, Cubans to Castro, and none of them were worth subjugating oneself to
None of them were worth being put on a pedestal
None of them were greater than you or I
Gorski is NOT the greater good
Gorski has a degree in “B.S.” from the University of Michigan
I do not have a “B.S.” degree
I’m the one NOT full of“B.S.”
Now that sounds like a story ripe for a journalistic investigation
So, I guess that means Bob Blaskiewicz’s fave “journalist,” Liz Szabo, and USA TODAY, are out of the running for this type of “reporting”
But look on the bright side:
“In his new role, he will work with the Samuel Silver, M.D., Ph.D., who is the MiBOQI program director, as well as assistant dean for Research and professor of Internal Medicine/Hematology-Oncology at the University of Michigan Medical School”
Maybe “the Samuel Silver, M.D., Ph.D.” will be GorskGeeks“checks and balances” ====================================== “Our only goal is to promote high standards of science in medicine” ====================================== http://www.sciencebasedmedicine.org/editorial-staff/
======================================
====================================== Such risible hyperbole would induce fits of laughter in me if it weren’t such a complete lie ======================================
I’m just glad dad got outta Kellogg country while he could
—————————————————————— P.S.: Per Dr. David H. Gorski, anything which might erroneously be perceived as a lie about Burzynski, is NOT anything wrong, per Wayne State University[14] ======================================
David H. Gorski, M.D., Ph.D., F.A.C.S., is a racist and a natural born killer
That’s right !
Dr. Gorski hates #cancer
He’s a bigot when it comes to breast cancer
Gorski sleeps, breathes, and blogs about breast cancer
He is an academicsurgical oncologistspecializing in breast surgery and oncologic surgery(Surgical Oncology Attending) at the Barbara Ann Karmanos Cancer Institute, Detroit, Michiganspecializing in breast cancer surgery, where he also serves as team leader for the Breast Cancer Multidisciplinary Team(MDT) at the Barbara Ann Karmanos Cancer Center, Co-Chair, Cancer Committee, Barbara Ann Karmanos Cancer Center, medical director of the Alexander J. Walt Comprehensive Breast Center at the Barbara Ann Karmanos Cancer Center(2010-present), Co-Leader of the Breast Cancer Biology Program, and the American College of Surgeons Committee on Cancer(ACS CoC) Cancer Liaison Physician as well as Associate Professor of Surgery at the Wayne State University School of Medicine; Faculty (2008-present), and member of the faculty of the Graduate Program in Cancer Biology at Wayne State University, MiBOQI project director(clinical champion) for Karmanos Cancer Center, site project director of the Michigan Breast Oncology Quality Initiative, University of Michigan, Ann Arbor, Michigan, a partnership between Karmanos and the University of Michigan, the new program co-director(Co-Medical Director) of the Michigan Breast Oncology Quality Initiative(MiBOQI); a state-wide initiative to improve the quality of breast cancer care using evidence-based guidelines, serves as the co-director of the Comprehensive Breast Center and is co-leader of the Breast Cancer Biology Program at Karmanos and Wayne State University School of Medicine, a Wayne State University Physician Group surgeon and chief of the Section of Breast Surgery(Breast Surgery Section) for the Wayne State University School of Medicine (2009-present), serves as an associate professor of surgery and Oncology at Wayne State University School of Medicine, Detroit, Michigan, and Treasurer and on the Board of Directors, and also serves the Institute for Science in Medicine as head of its childhood immunization committee
Prior to joining Karmanos and Wayne State University School of Medicine, was an associate professor of surgery at The Cancer Institute of New Jersey and the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, NJ, as well as a member of the Joint Graduate Program in Cell & Developmental Biology at Rutgers University in Piscataway, N.J.
1984 – Graduation with Honors and High Distinction in Chemistry
1994 – MetroHealth Medical Center Resident Research
He attended the University of Michigan Medical School, received his B.S. in chemistry from the University of Michigan, Ann Arbor, Michigan, medical degree (M.D.) from the University of Michigan Medical School, Ann Arbor, Michigan, University of Chicago Fellowship, Surgical Oncology, Case Western Reserve University / University Hospitals Case Medical Center Internship, General Surgery, Case Western: Reserve University / University Hospitals Case Medical Center Residency, General Surgery, and received his Ph.D. in cellular physiology at Case Western Reserve University, Cleveland, Ohio
1998 – American Board of Surgery
Assistant Professor of Surgery UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey
1999 – 2006: Assistant Professor of Surgery
1999 – 2008: Active, Surgical Oncology and General Surgery
2005 – 2006: Active, Surgical Oncology and General Surgery
2007 – American Society of Clinical Oncology Advanced Clinical Research
2007 – Conquer Cancer Foundation of ASCO and Breast Cancer Research Foundation Advanced Clinical Research Award in Breast Cancer
2006 – 2008: Associate Professor of Surgery
Faculty, General Surgery, St. Peter’s University Hospital, New Brunswick, New Jersey
Attending Surgeon, Trauma Services, Lutheran General Hospital, Park Ridge, Illinois
2015 – Michigan State Medical License (Active through)
2015 – Ohio State Medical License (Active through)
Managing Editor of the Science-Based Medicine weblog, as well as a once-weekly contributor
SBM exists to take a skeptical, science-based view of medicine in general and in particular the infiltration of pseudoscientific practices into medicine, even in academic medical centers
These entities must have felt lucky to add a University of Michigan alum to their toolbox, a wolverine; a creature also known as a glutton or skunk bear
Who would doubt that Gorski would be a gluttonfor punishment when it comes to raising a big stink about breast cancer issues?
Surely he was aware: Detroit, Michigan; the most populous city in the state of Michigan, with a population of 701,475 (2012) (9,883,360 – Michigan), 575,321 (81.4%) being African American (Black); a little less than six times the national average (82.7% – 2010 / about 83% – 2012) (Michigan – 14.2% – 2010), 369,616 Females (52.7% – 2012 / 53% – 2010) (Michigan 50.9%)
No doubt he knew that the most recent American Cancer Society Cancer Facts & Figures, noted:
——————————————————————
• Studies have documented unequal receipt of prompt, high-quality treatment for African American women compared to white women
• African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective
• African Americans and other racial minorities are underrepresented in clinical trials, which makes it more difficult to assess efficacy of cancer therapies among different racial/ethnic groups
• African Americanshave highest death rate and shortest survival of any racial and ethnic group in US for most cancers
• Life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years)
• Higher death rate in African American women compared to white womenoccurs despite lower cancer incidence rate
• Racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women
• African American womenhave higher death rates overall and for breast and several other cancer sites
• African Americanscontinue to have lower 5-year survival overall:
69% – whites 60% – African Americans
and for each stage of diagnosis for most cancer sites
• Evidence aggressive tumor characteristics more common inAfrican American than white women
—————————————————————— Gorskiworked tirelessly to address the problem, by appearing on TV, radio, Internet radio, in articles and on his blogs
Soon, the locals were remarking about the “Gorski Patient Group” web-site which was set up to display anecdotal stories of breast cancer patients who were “cured” by Gorski
How has his hard work paid off ?
—————————————————————— Are these Dr. David H. Gorski’s “success stories” ?
—————————————————————— African American women breast cancer death rates per 100,000 (MICHIGAN)
—————————————————————– 34.3☝2005_-_2009 (State with 11 most) 2013-2014
33.8👇2003_-_2007 (State with 11 most) 2011-2012
34.7👇2001_-_2005 (State with 17 most) 2009-2010
35.4👇2000_-_2003 (State with 19 most) 2007-2008
36.2👇1997_-_2001 (State tied with 20 most) 2005-2006
—————————————————————— BREAST CANCER
—————————————————————— WHITE-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
118.7👇2006_-_2010 (2013-2014)
120.1👇2004_-_2008 Incidence (2011-2012)
124.3👇2002_-_2006 (2009-2010)
129.9👇2000_-_2004 (2007-2008) 133.9☝1998_-_2002 (2005-2006) 132.1☝1996_-_2000 (2003-2004)
—————————————————————— WHITE-MORTALITY-MICHIGAN (per 100,000)
——————————————————————
22.8👇2006_-_2010 (2013-2014)
23.4👇2003_-_2007 Mortality (2011-2012)
23.8👇2002_-_2006 (2009-2010)
24.6👇2000_-_2004 (2007-2008)
25.9👇1998_-_2002 (2005-2006)
27.3👇1996_-_2000 (2003-2004)
—————————————————————— AFRICAN AMERICAN-INCIDENCE-MICHIGAN (per 100,000)
—————————————————————— 119.4☝2006_-_2010 (2013-2014)
119.2👇2004_-_2008 Incidence (2011_-_2012) 121.0☝2002_-_2006 (2009-2010)
119.0👇2000_-_2004 (2007-2008)
120.6👇1998_-_2002 (2005-2006) 121.4☝1996_-_2000 (2003-2004)
—————————————————————— AFRICAN AMERICAN-MORTALITY-MICHIGAN (per 100,000)
—————————————————————— 34.3☝2006_-_2010 (2013-2014)
33.8👇2003_-_2007 Mortality (2011-2012)
34.6👇2002_-_2006 (2009-2010)
35.0👇2000_-_2004 (2007-2008)
36.0👇1998_-_2002 (2005-2006)
36.9👇1996_-_2000 (2003-2004)
—————————————————————— HISPANIC-INCIDENCE-MICHIGAN (per 100,000)
——————————————————————
80.1👇2006_-_2010 (2013-2014) 92.7☝2004_-_2008 Incidence (2011-2012)
—————————————————————— HISPANIC-MORTALITY-MICHIGAN (per 100,000)
—————————————————————— 15.8☝2006_-_2010 (2013-2014) 14.26☝2003_-_2007 Mortality (2011-2012)
—————————————————————— INCIDENCE-MICHIGAN (per 100,000) COMBINED
—————————————————————— 119.4☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
118.7👇2006_-_2010 WHITE (2013-2014)
80.1👇2006_-_2010 HISPANIC (2013-2014)
—————————————————————— MORTALITY-MICHIGAN (per 100,000) COMBINED
—————————————————————— 34.3☝2006_-_2010 AFRICAN AMERICAN (2013-2014)
22.8👇2006_-_2010 WHITE (2013-2014) 15.8☝2006_-_2010 HISPANIC (2013-2014)
—————————————————————— MICHIGAN – Estimated New Breast Cancer Cases:
—————————————————————— 8,140☝2013 (State with 8th most)
7,710👇2012 (State with 8th most) 7,890☝2011 (State with 8th most) 7,340☝2010 (State with 8th most) 6,480☝2009 (State with 8th most)
6,120👇2008 (State with 9th most)
7,210👇2005 (State with 9th most)
7,270👇2004 (State with 9th most) 7,500☝2003 (State with 8th most) 7,300☝2002 (State with 8th most)
—————————————————————— Are these Dr. David H. Gorski’s “success stories” ?
—————————————————————— MICHIGAN – Estimated Breast Cancer Deaths:
—————————————————————— 1,360☝2013 (State with 8th most) 1,350☝2012 (State with 8th most)
1,320 – 2011 (State with 9th most)
1,320👇2010 (State with 10th most) 1,350☝2009 (State with 9th most)
1,310 👇2008 (State with 9th most)
1,320 👇2007 (State with 9th most)
1,360 👇2006 (State with 9th most) 1,380☝2005 (State with 9th most)
1,350👇2004 (State with 9th most)
1,400 – 2003 (State tied with 8th most) 1,400☝2002 (State tied with 8th most)
—————————————————————— MICHIGAN – Cancer Incidence Rates
——————————————————————
120.3 – 2013 (State with 32nd most)
120.3👇2012 (State with 30th most)
122.2👇2011 (State with 24th most)
124.2👇2010 (State with 17th most)
127.0👇2009 (State with 11th most)
128.8👇2008 (State with 13th most)
129.4👇2007 (State tied with 18th most)
132.4👇2006 (State with 14th most) 133.5☝2005 (State with 13th most) 132.0☝1996_-_2000 (State with 14th most) 2004 129.8☝1995_-_1999 (State with 23rd most)(31st State’s) 2003
109.9👇1994_-_1998 Michigan – Cancer Incidence Rates (2002) 132.0☝1996_-_2000 (State with 14th most) (2004) 129.8☝1995_-_1999 (State with 23rd most) (2003) 109.9☝1994_-_1998 (State with 20th most) (2002)
—————————————————————— MICHIGAN – Cancer Death Rates:
——————————————————————
24.0👇2013 (State tied with 11th most)
24.4👇2012 (State tied with 13th most)
24.5👇2011 (State tied with 16th most)
25.1👇2010 (State tied with 12th most)
25.3👇2009 (State tied with 17th most)
25.8👇2008 (State tied with 18th most)
26.6👇2007 (State tied with 14th most)
27. 5 – 2006 (State tied with 12th most)
27.5👇2005 (State tied with 13th most)
28.4👇1996_-_2000 (State tied with 14th most) (2004) 29.5☝1995_-_1999 (State tied with 14th most) 2003 24.8☝1994_-_1998 (State with 14th most) 2002
——————————————————————
The problem, is that, when the Hippocratic Oath
was mentioned, Gorski may have opted for the Hypocrite Oath
Rather than address the BILLIONS of dollars in fines which Big Pharma racked up, and Pharma’s seeming dedication to getting members of the unwitting public, to take medications for symptoms which they were not approved for; and thus possibly experience adverse effects those drugs cause, Gorski chose to NOT comment about his goose that might lay the golden (parachute) nest egg
Instead, he tried the Tricky-Dickytrickle-down theory of Hackademic Mudicine(“Quackademic Medicine”); which did NOT work when Richard Milhous (“War on Cancer”) Nixon was told:
“There’s a cancer on the Presidency”
What Gorski seems hilariously oblivious to, is that his opprobrium; to turn a phrase, applies to him:
—————————————————————— (.3:16)
——————————————————————
When he mentions:
“ineffective and potentially harmful medical practices that were not, that are not supported by evidence”
he may as well be saying, in regards to surgery, chemotherapy, and radiation:
“ineffective and potentially harmful medical practices that were, that are supported by evidence“
(the evidence that they do NOT work for everyone)
—————————————————————— (.3:42)
——————————————————————
To use his own words, he seems:
“confused, at best”
—————————————————————— (.4:45)
——————————————————————
He also displays:
“an animosity toward reason”
—————————————————————— (.4:49)
—————————————————————— “Nothing’s changed within 30 years
If anything, it’s worse”
—————————————————————— (.6:45)
——————————————————————
He states:
“Alternative = unproved”
There goes “Alternative Rock,” or the “alternative” to an attemptedGorskijoke: “happiness is a warm gun”
I’m somewhat surprised that Gorski has yet to classify antineoplastons as “Homeopathy: Ultra-diluted chemotherapy”
—————————————————————— (28:15)
——————————————————————
But he does rant that rival Cleveland Clinic where he had his residency, has been infiltrated by the Q.M.
—————————————————————— (39:10)
——————————————————————
And that his alma-mater, the University of Michigan has also queued in the “Quackademic” line
—————————————————————— (44:00)
——————————————————————
He bemoans the mighty wolverine:
“Again my alma-mater”
“I hang my head in shame”
—————————————————————— (44:10)
——————————————————————
And to add injury to insult, his “former employer,” UMDNJ(University of Medicine and Dentistry of New Jersey)-Robert Wood Johnson Medical School, New Brunswick, New Jersey, has also been bitten by the Quackademic Duck
I’m sure Gorski will be able to formulate a usual factoid #fail for his #failure to “cure” cancer, vis-a-vis “Orac”, the literary Hack, braying in the wilderness and awaiting his Red Badge of Courage
Maybe “too many people copulating” in Detroit, or too many Louisiana hurricane Katrina survivors added to the sandbox
Is Gorski a racist?
That’s up to all the African American women in Detroit, Michigan, to decide
Maybe he’s just a really bad hypocrite
NOr, maybe he needs to spend less time on the “hypocuresy,” and more time on the “CURE”
Maybe the African American women of Detroit, Michigan, and the United States of America should ask Gorski:
What have you done for me lately ?
——————————————————————
—————————————————————— “And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise”
—————————————————————— NO, Gorski, the United States’ 5th Circuit Court of Appeals claimed that antineoplastons (ANPs) are:
“…an unapproved drug, not ordinary “chemotherapy”
no matter how much YOU try to claim otherwise
What are you ?
A Saul Green closet communist who does NOT believe what the United States’ Federal Courtsrule ?
——————————————————————
——————————————————————
“Indeed, it was a blatant ploy, as Burzynski’s lawyer, Richard Jaffe, acknowledged, referring to one of his clinical trials as a “joke” and the others as a way to make sure there was a constant supply of new cancer patients to the Burzynski Clinic“
——————————————————————
—————————————————————— ” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials“
“As a result of the expansion of Dr. Burzynski’s medical practice, the financial condition of the medical practice has improved Dr. Burzynski’s ability to fund the Company’s operations”
—————————————————————— GorskGeek, my citations, references, and / or links, beat your NON-citations, NON-references, and / or NON-links ====================================== AMERICAN CANCER SOCIETY:
CANCER FACTS & FIGURES (2002-2014) ======================================
2002_-_2003 – 1 of every 4 deaths
====================================== Deaths – United States of America
—————————————————————— 2013 – almost 1,600 a day 2002-2012☝1,500+ a day
—————————————————————— Expected to Die – United States
—————————————————————— 2013☝580,350_-_(3,160 more than 2012)
2012☝577,190_-_(5,240 more than 2011)
2011☝571,950_-_(2,460 more than 2010)
2010☝569,490_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008) 2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005) 2005☝570,280_-_(6,580 more than 2004
2004☝563,700_-_(7,200 more than 2003)
2003☝556,500_-_(6,000 more than 2002)
2002☝555,500
—————————————————————— Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (1,940 less than 2012) 2012☝275,370 (3,850 more than 2011)
2011☝271,520 (1,230 more than 2010)
2010☝270,290 (490 more than 2009)
2009👇269,800 (1,730 less than 2008) 2008☝271,530 (1,430 more than 2007)
2007👇270,100 (3,460 less than 2006)
2006👇273,560 (1,440 less than 2005) 2005☝275,000 (2,190 more than 2004)
2004☝272,810 (2,210 more than 2003)
2003☝270,600 (3,300 more than 2002)
2002_-_267,300
—————————————————————— Estimated cancer deaths – African Americans expected to die from cancer:
——————————————————————
2013👇64,645 – 22.6% (2013-2014) 2011☝65,540 (About) (2011-2012)
2009☝63,360 (About) (2009-2010)
2007☝62,780 (About) (2007-2008)
—————————————————————— Estimated Breast Cancer Deaths (Women)
—————————————————————— 2013☝39,620 (14%) (110 more than 2012)
2012👇39,510 (14%) (10 less than 2011)
2011👇39,520 (15%) (320 less than 2010)
2010👇39,840 (15%) (330 less than 2009)
2009👇40,170 (15%) (310 less than 2008) 2008☝40,480 (15%) (20 more than 2007)
2007👇40,460 (15%) (2007-2008) (510 less than 2006) 2006☝40,970 (15%) (560 more than 2005)
2005☝40,410 (15%) (300 more than 2004)
2004☝40,110 (15%) (310 more than 2003)
2003☝39,800 (15%) (200 more than 2002)
2002 – 39,600 (15%)
—————————————————————— Estimated Deaths from Breast cancer expected to occur among African American women:
—————————————————————— 6,080☝2013 – 19% (2013-2014)
6,040☝2011 – 19% (2011-2012)
6,020☝2009 – 19% (2009-2010)
5,830☝2007 – 19% (2007-2008)
5,640☝(2005-2006)
5,640 – 1969-2002 – 18.4% – 2005 (2005-2006) ====================================== New Cancer Cases Expected to be diagnosed – USA
—————————————————————— 2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)
2008👇1,437,180 – ( 7,740 less than 2007) 2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002☝1,284,900
—————————————————————— Estimated New Cancer All (Women)
—————————————————————— 2013☝805,500 – (14,760 more than 2012)
2012☝790,740 – (16,370 more than 2011)
2011☝774,370 – (34,430 more than 2010)
2010☝739,940 – (26,720 more than 2009)
2009☝713,220 – (21,220 more than 2008)
2008☝692,000 – (13,940 more than 2007)
2007👇678,060 – (1,450 less than 2006) 2006☝679,510 – (16,640 more than 2005)
2005👇662,870 – (5,600 less than 2004) 2004☝668,470 – (9,670 more than 2003)
2003☝658,800 – (11,400 more than 2002)
2002_-_647,400
—————————————————————— Estimated New invasive Breast Cancer Cases: (Women)
—————————————————————— 2013☝232,340 (29%) (5,470 more than 2012)
2012👇226,870 (29%) (11,610 less than 2011) 2011☝238,480 (30%) (31,390 more than 2010)
2010☝207,090 (28%) (14,720 more than 2009)
2009☝192,370 (27%) (9,910 more than 2008)
2008☝182,460 (26%) (3,980 more than 2007)
2007👇178,480 (26%) (2007-2008) (34,440 less than 2006) 2006☝212,920 (31%) (1,680 more than 2005)
2005👇211,240 (32%) (4,660 less than 2004) 2004☝215,900 (32%) (4,600 more than 2003)
2003☝211,300 (32%) (7,800 more than 2002)
2002_-_203,500 (31%)
—————————————————————— Estimated new cases – new cancer cases expected to be diagnosed among African Americans:
—————————————————————— 2013☝176,620 (2013-2014)
2011☝168,900 (About) (2011-2012)
2009👇150,090 (About) (2009-2010) 2008☝182,460 (26%)
2007_-_152,900 (About) (2007-2008)
—————————————————————— Estimated new cases of in situ breast cancer expected to occur:
—————————————————————— 64,640☝(2013) (1,340 more than 2012)
63,300☝(2012) (5,650 more than 2011)
57,650☝(2011) (3,640 more than 2010)
54,010👇(2010) (8,270 less than 2009)
62,280👇(2009) (5,490 less than 2008) 67,770☝(2008) (5,740 more than 2007-2008)
62,030☝(2007-2008) (50 more than 2006)
61,980☝(2006) (3,490 more than 2005-2006)
58,490👇(2005-2006) (900 less than 2004) 59,390☝(2004) (3,690 more than 2003)
55,700☝(2003) (1,400 more than 2002)
54,300☝(2002)
—————————————————————— Estimated New Cancer Cases – African Americans – Breast
—————————————————————— 2013☝27,060 – 33% (2013-2014)
2011☝26,840 – 34% (2011-2012)
2009☝19,540 – 25% (2009-2010)
2007☝19,010 – 27% (2007-2008)
19,240 – 1979-2001 – 29.9% – 2005 (2005-2006)
—————————————————————— Estimated new cases of in situ breast cancer expected to occur = detection of below # of ductal carcinoma in situ (DCIS):
——————————————————————
54,944 (2013)
85% (2003-2012)
88% (2002)
1998-2002 accounted for about 85% of in situ breast cancers diagnosed (2005-2006)
1980-2001 – Incidence rates of DCIS increased more than sevenfold in all age groups, although greatest in women 50 and older (2005-2006)
—————————————————————— LEADING CAUSE OF DEATH
——————————————————————
2013 – breast cancer expected to be most commonly diagnosed cancer in women
—————————————————————— BREAST CANCER – 2nd
——————————————————————
2013 – Breast cancer 2nd most common cause of cancer death among African American women, surpassed only by lung cancer (2009-2012)
(2007)
——————————————————————
2003 – Breast cancer is 2nd among cancer deaths in women
2002-2003: 2nd leading cause of death
2002 – Breast cancer 2nd leading cause of death
————————————-
Breast cancer most common cancer among African American women
New Cases: Breast cancer most commonly diagnosed cancer among African American women
—————————————————————— BREAST CANCER – AFRICAN AMERICAN WOMEN
——————————————————————
34% – African American women most common cancer (2011-2012)
African American Women Most common cancer (2005-2006)
——————————————————————
2005 – African American women – more likely to die from at any age
—————————————————————— ESTIMATED WOMEN BREAST CANCER DEATHS
——————————————————————
19% – number of cancer deaths breast cancer in women (2007-2012)
——————————————————————
since 1990 – Death rates from breast cancer steadily decreased in women (2009-2010)
since 1990 – death rate from breast cancer in women decreased (2007-2008)
——————————————————————
1.9% – 2000-2009 cancer mortality rate for women of all races combined declined annually (2012-2013)
——————————————————————
1990-2006 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
2.2% – 1990-2004 cancer mortality rate for women of all races combined decreased annually (2007-2008)
decline larger among younger age groups (2007-2008)
——————————————————————
2.3% – 1990-2002 rate decreased annually – percentage of decline larger among younger age groups (2005-2006)
——————————————————————
2.3% – 1990-2000 breast cancer death rates decreased annually (2005-2006)
——————————————————————
1992-1998 – mortality rates declined significantly
largest decreases in younger women, both white and black (2002)
——————————————————————
1.6% – 1975-1991 – Breast Cancer Death Rates Increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 – breast cancer death rates increased annually (2005-2006)
——————————————————————
0.4% – 1975-1990 death rate for all races combined increased annually (2005-2008)
——————————————————————
rate for women of all races combined decreased annually (2007-2008)
decline larger among younger age groups (2007-2008)
—————————————————————— BREAST CANCER – OLDER WOMEN
——————————————————————
Older women much more likely to get breast cancer than younger women
—————————————————————— % FEMALE BREAST CANCER DEATH RATES (age)
——————————————————————
97% – 1998-2002 – age 40 and older (2005-2008)
96% – 1996-2000 – age 40 and older (2005-2006)
—————————————————————— WOMEN YOUNGER than 50
——————————————————————
3.0% – under age of 50 – Mortality from breast cancer declined faster for women (annually from 2005-2009) regardless of race/ethnicity (2013)
——————————————————————
2.3% – 1990-2001 Breast Cancer Death Rates decrease
largest decrease in < 50 (2005-2006)
——————————————————————
3.7% – 1991-2000 under 50 breast cancer Death rates decreased (2005-2006)
——————————————————————
3.3% – 1990-2004 – death rates decreased per year among women younger than 50 (2005c-2008)
——————————————————————
2.3% – 1990-2002 Death rates from breast cancer declined average per year in all women combined, with larger decreases in younger (<50 years) women (2006)
—————————————————————— WOMEN 50 and older
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
——————————————————————
2.0% – 50 and older – 1990-2004 – death rates decreased per year among women (2005-2008)
—————————————————————— WHITE WOMEN
——————————————————————
2.1% – 2000-2009 – breast cancer death rates declined per year in white women
——————————————————————
2.6% – 1992-2000 – breast cancer Death rates Whites (2005-2006)
——————————————————————
2.4% – 1990-2004 female breast cancer death rates declined per year in whites (2005-2008)
——————————————————————
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
—————————————————————— AFRICAN AMERICAN WOMEN – ALL CANCERS
——————————————————————
1.5% – since 1999 – Death rates among women (African Americans for all cancers combined) per year have been decreasing (2011-2012)
—————————————————————— AFRICAN AMERICAN WOMEN BREAST CANCER DEATHS
——————————————————————
black women more likely to die of breast cancer than white women (2012-2013)
——————————————————————
2005-2006 African American women more likely to die from breast cancer at every age
——————————————————————
41% – 2005-2009 African American women had higher death rate than white women despite lower incidence rate
39% – 2003-2007 – African American women had higher death rate than white women, despite lower incidence rate (2011-2012)
difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2011-2012)
37% – 2001-2005 – African American women had higher death rate than white women (2009-2010)
higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2009-2010)
difference accounts for more than one-third (37%) of overall cancer mortality disparity between African American and white women (2009-2010)
higher breast cancer mortality rate among African American women compared to white women occurs despite lower incidence rate (2007)
notable, striking divergence in long-term breast cancer mortality rates trends between African American and white women (2005-2008)
36% – by 2004 – death rates higher in African Americans than white women (2007-2008)
37% – by 2002 – death rates higher in African American women than white women (2005-2006)
36% – 2000-2003 – death rates higher in African American women than white women (2007)
difference accounts for one-third of excess cancer mortality experienced by African American women compared to white women (2007)
32% – 2000 – Breast Cancer Death rate higher in African American women even though had lower incidence rates (2005-2006)
—————————————————————— AFRICAN AMERICAN WOMEN – 50 and older
——————————————————————
1.2% – 50 and older – 1992-2012 – per year – women (2011-2012)
2.0% – 50 and older – Breast Cancer Death Rates – per year (2009-2010)
——————————————————————
1.2% – 50 and older – decrease in breast cancer death rates smaller in African American than white women (2009-2010)
1.1% – 50 and older – 1991-2007 – African American women Breast cancer death rates declined annually (2007)
2.0% – 50 and older – 1990-2000 – breast cancer Death rates decreased (2005-2006)
——————————————————————
1990 – 50 and older – Breast Cancer Death Rates Increase predominantly due to
—————————————————————— AFRICAN AMERICAN WOMEN – under 50
——————————————————————
2.0% – 1992-2012 – decrease larger in women under 50 – declined thereafter per year (2011-2012)
1.9% – 1992-2009 – decrease larger in women under 50 – declined thereafter per year (2009-2010)
resulted in growing disparity
3.3% per year – larger decreases in women younger than 50 – Breast Cancer Death Rates (2009-2010)
——————————————————————
1.9% – 1991_-_2007 – decrease larger in women under 50 – African American women Breast cancer death rates declined annually per year
—————————————————————— AFRICAN AMERICAN WOMEN
——————————————————————
2000-2009 – death among females, rate of decline similar
As result, overall racial disparity narrowed
——————————————————————
2000-2009 death rate declined faster among African Americans females rate of decline than whites
1.5% – 2000-2009 African Americans females rate of decline per year (2013-2014)
1.4% – 2000-2009 whites rate of decline per year (2013-2014 )
——————————————————————
1.4% – 2000-2009 – breast cancer death rates declined more slowly per year in African American women
——————————————————————
1990-2002
African American women benefited less than white women from advances (2005-2008)
——————————————————————
1.1% – breast cancer death rates African Americans (2005-2006)
——————————————————————
1.6% – 1995-2004 – female breast cancer death rates declined per year in African Americans (2007-2008)
1.0% – 1990-2002 female breast cancer death rates declined per year – African Americans (2005-2006)
——————————————————————
early 1990s – Death rates among African Americans for all cancers combined have been decreasing (2011-2012)
——————————————————————
breast cancer death rates have declined more slowly in African American women compared to white women, which has resulted in growing disparity (2011-2012)
——————————————————————
gap much smaller among women
racial difference in overall cancer death rates due largely to cancers of breast and colorectum in women
racial disparity has widened for breast cancer in women (2011-2012)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women began in (2007-2008)
——————————————————————
early 1980s – breast cancer death rates for white and African American women approximately equal (2007)
——————————————————————
30% – early 1980’s-2000 – disparity between African American and white Deaths (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
early 1980s – breast cancer death rates for white and African American women
similar (2011-2014)
equal (2009-2010)
early 1980’s – Breast Cancer Death Rates equal – African American / White (2005-2006)
——————————————————————
1.5% – 1975-1992 – Breast cancer death rates among African American women increased annually (2009-2012)
1.6% – 1975-1991 – African American women Breast cancer death rates increased annually (2007)
——————————————————————
1975-2007 – death rates for all cancers combined continued to be substantially higher among African Americans than whites (2011-2012)
—————————————————————— AFRICAN AMERICAN WOMEN BREAST CANCER DEATH RATE RATIOS per 100,000 women
——————————————————————
35.4 – African American – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
26.4 – White – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
1.3 – African American / White Ratio – 1997-2001 – Breast Cancer Death Rate Ratios per 100,000 (2005-2006)
—————————————————————— HISPANIC / LATINA WOMEN
——————————————————————
2.4% – 1995-2004 female breast cancer death rates declined per year in Hispanics / Latinas (2007-2008)
1.8% – 1990-2002 female breast cancer death rates declined per year in Hispanics / Latinas (2005-2006)
1.4% – breast cancer Death rates Hispanics (2005-2006)
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
—————————————————————— ASIAN AMERICAN / PACIFIC ISLANDER WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among Asian Americans/Pacific Islanders (2007-2008)
1.1% – breast cancer Death rates Asian and Pacific Islanders (2005-2006)
1.0% – 1990-2002 female breast cancer death rates declined per year – Asian Americans / Pacific Islanders (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
—————————————————————— AMERICAN INDIAN / ALASKA NATIVE WOMEN
——————————————————————
1995-2004 female breast cancer death rates remained unchanged among American Indians / Alaska Natives (2007-2008)
1990-2002 female breast cancer death rates did not decline in American Indian / Alaska Natives (2005-2006)
——————————————————————
1990-2002
women of other racial and ethnic groups benefited less than white women from advances (2005-2008)
——————————————————————
breast cancer Death rates American Indian and Alaska Native – constant (2005-2006)
—————————————————————— DEATHS – 2007-2008
——————————————————————
40,460 – Deaths – All ages (2007-2008)
23,510 – Deaths – 65 and older (2007-2008)
16,950 – Deaths – Younger than 65 (2007-2008)
31,320 – Deaths – 55 and older (2007-2008)
9,140 – Deaths – Younger than 55 (2007-2008)
37,630 – Deaths – 45 and older (2007-2008)
2,830 – Deaths – Younger than 45 (2007-2008)
—————————————————————— MORTALITY (DEATH) RATES
——————————————————————
31.0 – Black – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
24.3 – White – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
14.8 – Hispanic – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
12.4 – American Indian / Alaskan Native – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
11.0 – Asian / Pacific Islander – Mortality – 1992-1998 – Mortality Rates* by Site, Race, and Ethnicity (2002)
—————————————————————— WHITE WOMEN – MORE LIKELY TO DEVELOP BREAST CANCER
——————————————————————
Combining all age groups, white (non-Hispanic) women more likely to develop breast cancer than black women
—————————————————————— PROBABILITY of DEVELOPING BREAST CANCER in NEXT 10 YEARS (Age)
—————————————————————— 20
——————————————————————
20 – 0.05% – 1 in 2,152 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
20 – 0.05% – 1 in 1,985 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
20 – 0.05% – 1 in: 1,837 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— 30
——————————————————————
30 – 0.44% – 1 in: 229 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
30 – 0.43% – 1 in: 234 – probability of developing breast cancer in next 10 years (2007-2008)
——————————————————————
30 – 0.40% – 1 in 251 – Probability of developing Breast Cancer in next 10 years (2005-2006)
—————————————————————— 40
——————————————————————
40 – 1.46% – 1 in: 68 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
40 – 1.45% – 1 in 69 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
40 – 1.43% – 1 in: 70 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— 50
——————————————————————
50 – 2.78% – 1 in 36 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
50 – 2.73% – 1 in: 37 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
50 – 2.51% – 1 in: 40 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— 60
——————————————————————
60 – 3.82% – 1 in: 26 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
60 – 3.81% – 1 in 26 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
60 – 3.51% – 1 in: 28 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— 70
——————————————————————
70 – 4.31% – 1 in 23 – Probability of developing Breast Cancer in next 10 years (2005-2006)
——————————————————————
70 – 4.14% – 1 in: 24 (2000-2002) probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
70 – 3.88% – 1 in: 26 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— LIFETIME RISK
——————————————————————
13.2% – 1 in 8 – 2005-2006 Currently, woman living in US has, or, lifetime risk of developing breast cancer
——————————————————————
13.22% – Lifetime risk – 1 in: 8 – 2000-2002 probability of developing breast cancer in next 10 years: † (2005-2006)
——————————————————————
12.28% – Lifetime risk – 1 in: 8 – probability of developing breast cancer in next 10 years (2007-2008)
—————————————————————— AFRICAN AMERICAN LIFE EXPECTANCY
——————————————————————
2007 – life expectancy lower for African Americans than whites among women
(76.5 vs. 80.6 years) (2011-2012)
—————————————————————— DEVELOPING INVASIVE BREAST CANCER
——————————————————————
1 in 8 – 2013 – chance of developing invasive breast cancer during lifetime
——————————————————————
1 in 8 – 12.3% – Currently, woman living in US has lifetime risk of developing breast cancer (2007-2008)
——————————————————————
about 1 in 11 – 1975
——————————————————————
1 in 11 – 1970s – lifetime risk of being diagnosed with breast cancer (2007-2008)
——————————————————————
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2005-2006)
—————————————————————— INVASIVE BREAST CANCER – by age (2007-2008)
——————————————————————
178,480 – All ages
72,520 – 65 and older
105,960 – Younger than 65
124,300 – 55 and older
54,180 – Younger than 55
162,330 – 45 and older
16,150 – Younger than 45
—————————————————————— INVASIVE BREAST CANCER – by # (2007-2008)
——————————————————————
178,480 – All ages
162,330 – 45 and older
124,300 – 55 and older
105,960 – Younger than 65
72,520 – 65 and older
54,180 – Younger than 55
16,150 – Younger than 45
—————————————————————— INVASIVE BREAST CANCER
——————————————————————
0.3% – 1987-2002 – Incidence Trends: increased per year (2005-2006)
————————————-
—————————–
4% (almost) – 1980-1987 – increased (almost +4% a year) Incidence Trends (2005-2006)
—————————————————————— age 40-49
——————————————————————
Since 1987 – age 40-49 – incidence rates of invasive breast cancer have slightly declined (2005-2006)
3.5% – 40-49 (age) – 1980-1987 – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
—————————————————————— age 50 and older
——————————————————————
Since 1987 – 50 and older – incidence rates of invasive breast cancer have continued to increase among women, though at much slower rate (2005-2006)
4.2% – 50 and older – incidence rates of invasive breast cancer increased among women per year – Incidence Trends: Invasive Breast Cancer (2005-2006)
—————————————————————— Under 40
——————————————————————
Under 40 – remained essentially constant (2005-2006)
Since 1987 – younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
—————————————————————— Invasive Breast Cancer
——————————————————————
1975-2000 – Invasive Breast Cancer (2005-2006):
4% – 40 and older – increased 1980-1987 then stabilized (2005-2006)
——————————————————————
1992-2002 – overall incidence rates did not change significantly among whites, African Americans, and Hispanics / Latinas (2005-2006)
——————————————————————
1.3% – Hispanics – increased overall (2005-2006)
——————————————————————
0.9% – Whites – increased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
—————————————————————— Asian Americans / Pacific Islanders
——————————————————————
2.1% – 1992-2002 – Asian and Pacific Islanders – overall incidence rates increased overall (2005-2006)
1.5% – 1992-2002 – Asian Americans / Pacific Islanders – overall incidence rates increased per year (2005-2006)
trends in invasive female breast cancer incidence rates (2005-2006)
—————————————————————— American Indian / Alaska Natives
——————————————————————
3.7% – American Indian / Alaska Native – decreased overall (2005-2006)
3.5% – 1992-2002 – American Indian / Alaska Natives – overall incidence rates decreased per year (2005-2006)
trends in invasive female breast cancer incidence rates (2005-2006)
—————————————————————— essentially constant – Incidence Trends
——————————————————————
1973-1980 – essentially constant – Incidence Trends (2005-2006)
——————————————————————
African Americans more likely to be diagnosed at later stage of disease when treatment choices are more limited and less effective (2013-2014)
—————————————————————— MEDIAN AGE of DIAGNOSIS
——————————————————————
62 – median age of diagnosis for -white women
——————————————————————
57 – median age of diagnosis for African American women
—————————————————————— DIAGNOSIS at LOCAL STAGE
——————————————————————
61% – breast cancers diagnosed among white women at local stage (2011-2012)
——————————————————————
51% (Only about half) – of breast cancers diagnosed among African American women are local stage (2011-2014)
—————————————————————— MEDIAN AGE AT TIME OF BREAST CANCER DIAGNOSIS
——————————————————————
61 – 2000_-_2004 median age at time of breast cancer diagnosis (2007-2008)
61 – 1998_-_2002 median age at time of breast cancer diagnosis
——————————————————————
61 – means 50% of women who developed breast cancer were 61 or younger (2007-2008)
50% of women who developed breast cancer were age 61 or younger 1998_-_2002
——————————————————————
61 – 50% were older than 61 when diagnosed (2007-2008)
50% were older than age 61 when diagnosed 1998_-_2002
—————————————————————— 2005_-_2009 % / age DIAGNOSED with BREAST CANCER
——————————————————————
61 – median age for breast cancer diagnosis
0.0% – under age 20
1.8% – between 20-34
9.9% – between 35-44
22.5% – between 45-54
24.8% – between 55-64
20.2% – between 65-74
15.1% – between 75-84
5.7% – 85+
—————————————————————— 2005_-_2009 % / age DIAGNOSED with BREAST CANCER by % (SEER, 2012)
——————————————————————
24.8% – between 55-64
22.5% – between 45-54
20.2% – between 65-74
15.1% – between 75-84
9.9% – between 35-44
5.7% – 85+
1.8% – between 20-34
0.0% – under age 20
—————————————————————— IN SITU BREAST CANCER – by age (2007-2008)
——————————————————————
62,030 – All ages
21,510 – 65 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
54,390 – 45 and older
7,640 – Younger than 45
—————————————————————— IN SITU BREAST CANCER – by # (2007-2008)
——————————————————————
62,030 – All ages
54,390 – 45 and older
40,520 – Younger than 65
37,110 – 55 and older
24,920 – Younger than 55
21,510 – 65 and older
7,640 – Younger than 45
—————————————————————— NEW CASES – IN SITU BREAST CANCER
——————————————————————
increase observed in all age groups, although greatest in women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer leveled off among women 50 and older (2007-2008)
——————————————————————
Since 2000 – incidence rates of in situ breast cancer have continued to increase in younger women (2007-2008)
——————————————————————
80% – 2000-2004 – Most in situ breast cancers are ductal carcinoma (DCIS), which accounted for about 80% of in situ breast cancers diagnosed (2007-2008)
——————————————————————
2000-2004 – Lobular carcinoma in situ (LCIS) less common than DCIS, accounting for about 10% of female in situ breast cancers diagnosed (2007-2008)
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer (2007-2008)
increase limited to women older than age 40 and largely to postmenopausal women (2007-2008)
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
12% – Lobular carcinoma in situ (LCIS) less common than DCIS
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer
increase limited to women older than 40 and largely to postmenopausal women
——————————————————————
1980s and 1990s – Incidence rates of in situ breast cancer increased rapidly (2007-2008)
—————————————————————— New cancer cases in women expected to be newly diagnosed among African Americans:
——————————————————————
2013 – 82,080 (About)
——————————————————————
19% – breast cancer in women (2007-2008)
——————————————————————
2002 – Breast cancer ranks 2nd among cancer deaths in women
——————————————————————
2002-2003: 2nd leading cause of death
—————————————————————— African American women expected to die from cancer:
——————————————————————
African Americans have the highest death rate and shortest survival of any racial and ethnic group in the US for most cancers
(2007-2014)
African Americans have the highest mortality rate of any racial and ethnic group in the US for most cancers
(2005-2006)
——————————————————————
higher death rate in African
American women compared to white women occurs despite lower cancer incidence rate (2013-2014)
——————————————————————
African American women have higher death rates overall and for breast and several other cancer sites (2013-2014)
——————————————————————
15% – 2009 – death rate for all cancers combined continued to be higher in African American women than in white women (2013-2014)
——————————————————————
racial difference in overall cancer death rates is due largely to cancers of the breast and colorectum in women (2013-2014)
——————————————————————
overall racial disparity in cancer death rates decreasing (2013-2014)
——————————————————————
16% – 2007 – death rate for all cancers combined higher in African American women than white women (2011-2012)
——————————————————————
37% – by 2002 – death rates higher in African Americans than white women (2005-2006)
——————————————————————
since early 1990s – death rates among African Americans for all cancers combined have been decreasing (2013-2014)
——————————————————————
30% – early 1980’s–2000 – Deaths disparity between African American and white (2005–2006)
——————————————————————
1975-2009 – Despite declines, death rates for all cancers combined continued to be higher among African Americans than whites (2013-2014)
——————————————————————
1992-2014 – Breast cancer death rates among African American women declined
——————————————————————
1.4% per year – 2000-2009 – breast cancer death rates declined more slowly in African American women
——————————————————————
2.1% per year – 2000-2009 – breast cancer death rates declined white women
——————————————————————
early 1980s – breast cancer death rates for white and African American women similar
——————————————————————
1975-1992 – Breast cancer death rates among African American women increased
resulted in growing disparity
——————————————————————
through 1998 – breast cancer incidence rates among young white women continued to increase more slowly (2002)
——————————————————————
1980s – 4.5% per year increase (2002)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
1992-1998 – mortality rates declined significantly – largest decreases in younger women, both white and black (2002)
—————————————————————— 1992-1998 – Incidence and Mortality Rates* by Site, Race, and Ethnicity (2002)
—————————————————————— Incidence
——————————————————————
115.5 – White
101.5 – Black
78.1 – Asian / Pacific Islander
50.5 – American Indian / Alaskan Native
68.5 – Hispanic
—————————————————————— Mortality
——————————————————————
31.0 – Black
24.3 – White
14.8 – Hispanic
12.4 – American Indian / Alaskan Native
11.0 – Asian / Pacific Islander
—————————————————————— Cancer Facts & Figures for African Americans 2005-2006
—————————————————————— 1995-2000 (2001) – Diagnosed
Female breast (2005-2006):
—————————————————————— Localized
——————————————————————
64% – White (2005-2006)
53% – African American (2005-2006)
—————————————————————— Regional
——————————————————————
35% – African American (2005-2006)
28% – White (2005-2006)
—————————————————————— Distant
——————————————————————
9% – African American (2005-2006)
5% – White (2005-2006)
—————————————————————— Unstaged
——————————————————————
3% – African American (2005-2006)
2% – White (2005-2006)
—————————————————————— 2005-2006 – Cancer Incidence Rates Ratios per 100,000 (1975-2001)
——————————————————————
1997-2001 – Breast (2005-2006)
143.2 – White (2005-2006)
118.6 – African American (2005-2006)
0.8 – African American / White Ratio (2005-2006)
—————————————————————— 2005-2006 – Cancer Death Rate Ratios per 100,000
——————————————————————
1997-2001 – Breast (2005-2006)
35.4 – African American (2005-2006)
26.4 – White (2005-2006)
1.3 – African American / White Ratio (2005-2006)
——————————————————————
Most common cancer among African American Women (2005-2006)
——————————————————————
17% lower incidence rate in African American than White (2005-2006)
——————————————————————
under 40 – higher incidence rate in African American than White (2005-2006)
—————————————————————— 25 years incidence:
——————————————————————
1999-2001 – leveling off (2005-2006)
1986-1999 – less rapid increase (2005-2006)
1978-1986 – rapid increase (2005-2006)
1975-1978 – stable (2005-2006)
—————————————————————— Breast Cancer Death Rates Increased (2005-2006):
——————————————————————
1975-1991 – + 1.6% – annually (2005-2006)
——————————————————————
1991 – decided annually: particularly in women younger than 50 (2005-2006)
—————————————————————— Breast Cancer Death Rates (2005-2006):
——————————————————————
early 1980’s – equal – African American / White (2005-2006)
——————————————————————
2000 – 32% – higher African American (2005-2006)
——————————————————————
Death rate higher in African American even though had lower incidence rates (2005-2006)
—————————————————————— Rate per 100,000
——————————————————————
White
African American
Asian or Pacific Islander
Hispanic
American Indian or Alaska Native
—————————————————————— 1996-2000 – Incidences:
140.8 – White
121.7 – African American
97.2 – Asian or Pacific Islander
89.8 – Hispanic
58 – American Indian or Alaska Native
—————————————————————— 1996-2000 – Deaths
35.9 – African American
27.2 – White
17.9 – Hispanic
14.9 – American Indian or Alaska Native
12.5 – Asian or Pacific Islander
—————————————————————— Estimated New In Situ Cases:
——————————————————————
2003_-_100 – < 30
2005 – 1,600 – Under 40
2003 – 2,100 – 30-39
2005 – 56,890 – 40 and older
2005 – 13,760 – Under 50
2003 -12,600 – 40-49
2005 – 44,730 – 50 and older
2005 – 37,040 – Under 65
2003 – 15,700 – 50-59
2005 – 21,450 – 65 and older
2003 – 11,500 – 60-69
2003 – 10,100 – 70-79
2003 – 3,500 – 80 +
2005 – 58,490 – All ages
TOTAL
2003 – 55,700
——————————————————————
2003_-_100 – 0.2%
2003 – 2,100 – 3.8%
2003 – 12,600 – 22.6%
2003 – 15,700 – 28.2%
2003 – 11,500 – 20.6%
2003 – 10,100 – 18.1%
2003 – 3,500 – 16.3
TOTAL
2003 – 100.0%
—————————————————————— Estimated New Invasive Cases:
——————————————————————
2003 – 1,000 – < 30
2005 – 9,510 – Under 40
2003 – 10,500 – 30-39
2005_-_201,730 – 40 and older
2005 – 45,780 – Under 50
2003 – 35,500 – 40-49
2005_-_165,460 – 50 and older
2005_-_123,070 – Under 65
2003 – 48,700 – 50-59
2005 – 88,170 – 65 and older
2003 – 43,100 – 60-69
2003 – 45,600 – 70-79
2003 – 27,000 – 80 +
2005_-_211,240 – All ages
TOTAL
2003 – 55,700 –
——————————————————————
2003 – 1,000 – 0.5%
2003 – 10,500 – 5.0%
2003 – 35,500 – 16.8%
2003 – 48,700 – 23.0%
2003 – 43,100 – 20.4%
2003 – 45,600 – 21.6%
2003 – 27,000 – 12.8%
TOTAL
2003 – 100.00%
—————————————————————— Deaths:
——————————————————————
2003_-_100 – < 30
2005 – 1,110 – Under 40
2003 – 1,300 – 30-39
2005 – 39,300 – 40 and older
2005 – 5,590 – Under 50
2003 – 4,300 – 40-49
2005 – 34,820 – 50 and older
2005 – 17,470 – Under 65
2003 – 7,000 – 50-59
2005 – 22,940 – 65 and older
2003 – 7,400 – 60-69
2003 – 9,500 – 70-79
2003 – 10,100 – 80 +
2005 – 40,410 – All ages
TOTAL
2003 – 39,800
——————————————————————
2003_-_100 – 0.3%
2003 – 1,300 – 3.3%
2003 – 4,300 – 10.8%
2003 – 7,000 – 17.6 %
2003 – 7,400 – 18.6%
2003 – 9,500 – 23.9%
2003 – 10,100 – 25.4%
TOTAL
2003 – 100.0
——————————————————————
1990 – Increase since predominantly due to women 50 and older
——————————————————————
1998-2002 accounting for female in situ breast cancers diagnosed (2005-2006):
——————————————————————
12% – Lobular carcinoma in situ (LCIS) less common than DCIS
Similar to DCIS, overall incidence rate of LCIS increased more rapidly than incidence of invasive breast cancer
increase limited to women older than 40 and largely to postmenopausal women
—————————————————————— 1990-2001 (2005-2006):
——————————————————————
2.3% – decrease
largest decrease in < 50
—————————————————————— 1998-2002 women aged 40 and older (2005-2006):
——————————————————————
95% – new cases
97% – breast cancer deaths
—————————————————————— 1996-2000 Women 40 and older (2005-2006):
——————————————————————
94% – New Cases
96% – Deaths
——————————————————————
0.3% per year – Incidence rates declined slightly among white females (2013-2014)
—————————————————————— 1996-2002 (2005-2006):
——————————————————————
20-24 – 1.3 per 100,000 lowest incidence rate – 1998-2002 (2005-2006)
75-79 – 499.0 per 100,000 highest incidence rate – 1996-2000 (2005-2006)
—————————————————————— 2005-2006
•
White women higher incidence of breast cancer than African American women after 35
African American women slightly higher incidence rate before 35
African American women more likely to die from breast cancer at every age
—————————————————————— 2005
White – higher incidence rate than African American women after 40
African American – slightly higher incidence rate before 40
African American women – more likely to die from at any age
——————————————————————
2005-2006 incidence and death rates from breast cancer lower among women of other racial and ethnic groups than white and African American women
——————————————————————
2000-2009 – stable among African American females (2013-2014)
——————————————————————
1975-1980 essentially constant (2005-2006)
1980-1987 + almost 4% per year (2005-2006)
1987-2002 + 0.3% per year (2005-2006)
• Incidence Trends
Invasive Breast Cancer (2005-2006):
1973-1980 – essentially constant (2005-2006)
1980-1987 – + almost 4% year (2005-2006)
1987-2000 – 0.4% year (2005-2006)
—————————————————————— 1980-1987 incidence rates of invasive breast cancer increased among women (2005-2006):
——————————————————————
40-49 (3.5% per year) (2005-2006)
50 and older (4.2% per year) (2005-2006)
Since 1987
50 and older – rates have continued to increase among women , though at much slower rate (2005-2006)
40-49 -rates have slightly declined (2005-2006)
younger than 40 – relatively little change in incidence rates of invasive breast cancer in women (2005-2006)
1975-2000 – Invasive Breast Cancer (2005-2006):
4% – 40 and older increased 1980 – 1987 then stabilized (2005-2006)
Under 40 – remained essentially constant (2005-2006)
—————————————————————— 2005-2006 trends in invasive female breast cancer incidence rates:
——————————————————————
1992-2002
(1.5% per year) – overall incidence rates increased in Asian Americans / Pacific Islanders (2005-2006)
(3.5% per year) – decreased in American Indian/Alaska Natives (2005-2006)
did not change significantly among whites, African Americans, and Hispanics/Latinas (2005-2006)
1992-2000 – Invasive (2005-2006):
2.1% – Asian and Pacific Islanders – increased overall (2005-2006)
1.3% – Hispanics – increased overall (2005-2006)
0.9% – Whites – increased overall (2005-2006)
3.7% – American Indian and Alaska Native – decreased overall (2005-2006)
——————————————————————
African Americans – stabilized (2005-2006)
——————————————————————
since 1990 – death rate from breast cancer in women decreased (2005-2006)
——————————————————————
1975-1990
0.4% – death rate for all races combined increased annually (2005-2006)
•
1990-2002
2.3% – rate decreased annually
percentage of decline larger among younger age groups (2005-2006)
1990-2002
3.3% – death rates decreased per year among women younger than 50 (2005-2006)
2.0% – per year among women 50 and older (2005-2006)
African American women and women of other racial and ethnic groups have benefited less than white women from advances (2005-2006)
1990-2002 female breast cancer death rates declined (2005-2006):
2.4% – per year – whites (2005-2006)
1.8% – per year – Hispanics/Latinas (2005-2006)
1.0% – per year – African Americans and Asian Americans/Pacific Islanders (2005-2006)
did not decline in American Indian/ Alaska Natives (2005-2006)
——————————————————————
life expectancy lower for African Americans than whites among women (77.2 vs. 80.9 years) (2013-2014)
——————————————————————
As result, overall racial disparity narrowed (2013-2014)
——————————————————————
striking divergence in long-term mortality trends between African American and white females (2005-2006)
——————————————————————
early 1980s – disparity in breast cancer death rates between African American and white women appeared (2005-2006)
——————————————————————
1975-1990 – Death (2005-2006):
0.4% – increased annually (2005-2006)
——————————————————————
1990-2000
2.3% – decreased annually (2005-2006)
——————————————————————
1991-2000
3.7% – under 50 decreased (2005-2006)
——————————————————————
1990-2000
2.0% – 50 and older decreased (2005-2006)
—————————————————————— 1992-2000 – Death (2005-2006):
——————————————————————
2.6% – Whites (2005-2006)
1.4% – Hispanics (2005-2006)
1.1% – African Americans (2005-2006)
1.1% – Asian and Pacific Islanders (2005-2006)
American Indian and Alaska Native – constant (2005-2006)
—————————————————————— Probability of developing Breast Cancer in next 10 years:
——————————————————————
Age
——————————————————————
20 – 0.05% – 1 in 2,152 (2005-2006)
20 – 0.05% – 1 in 1,985 – 2000-2002 (2005-2006)†
——————————————————————
30 – 0.40% – 1 in 251 (2005-2006)
30 – 0.44% – 1 in: 229 – 2000-2002 (2005-2006)†
——————————————————————
40 – 1.45% – 1 in 69 (2005-2006)
40 – 1.46% – 1 in: 68 – 2000-2002 (2005-2006)†
——————————————————————
50 – 2.78% – 1 in 36 (2005-2006)
50 – 2.73% – 1 in: 37 – 2000-2002 (2005-2006)†
——————————————————————
60 – 3.81% – 1 in 26 (2005-2006)
60 – 3.82% – 1 in: 26 – 2000-2002 (2005-2006)†
——————————————————————
70 – 4.31% – 1 in 23 (2005-2006)
70 – 4.14% – 1 in: 24 – 2000-2002 (2005-2006)†
—————————————————————— Lifetime Probability (%) of Developing or Dying from Invasive Cancers by Race and Sex
—————————————————————— Developing
12.73 (1 in 8) – White (%) 2007-2009 (2013-2014)
10.87 (1 in 9) – African American (%) 2007-2009 (2013-2014)
Dying
3.25 (1 in 31) – African American (%) 2007-2009 (2013-2014)
2.73 (1 in 37) – White (%) 2007-2009 (2013-2014)
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
——————————————————————
13.22% – Lifetime risk – 1 in: 8
Comparison of Cancer Incidence Rates between African Americans and Whites
——————————————————————
123.2 – White Rate* 2005-2009 (2013-2014)
121.7 – White Rate* 2003-2007 (2011-2012)
130.6 – White Rate* 2001-2005 +
——————————————————————
118.1 – African American Rate* 2005-2009 (2013-2014)
114.7 – African American Rate* 2003-2007 (2011-2012)
117.6 – African American Rate* 2001-2005 +
——————————————————————
-5.1 – Difference† 2005-2009 (2013-2014)
-7.0 – Absolute Difference† 2003-2007 (2011-2012)
-13.1 – Absolute Difference† 2001-2005 +
——————————————————————
0.96 – Rate Ratio‡ 2005-2009 (2013-2014)
0.94 – Rate Ratio‡ 2003-2007 (2011-2012)
0.90 – Rate Ratio‡ 2001-2005 +
*Rates per 100,000 age adjusted to 2000 US standard population
†Difference is rate in African Americans minus rate in whites
†Absolute difference is rate in African Americans minus rate in whites
‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites
‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places
+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
—————————————————————— Comparison of Cancer Death Rates between African Americans and Whites
——————————————————————
31.6 – African American Rate* 2005-2009
32.4 – African American Rate* 2003-2007 (2011-2012)
33.5 – African American Rate* 2001-2005 +
——————————————————————
22.4 – White Rate* 2005-2009
23.4 – White Rate* 2003-2007 (2011-2012)
24.4 – White Rate* 2001-2005 +
——————————————————————
9.2 – Difference† 2005-2009
9.0 – Absolute Difference† 2003-2007 (2011-2012)
9.1 – Absolute Difference† 2001-2005 +
——————————————————————
1.41 – Rate Ratio‡ 2005-2009
1.39 – Rate Ratio‡ 2003-2007 (2011-2012)
1.37 – Rate Ratio‡ 2001-2005 +
*Rates per 100,000 and age adjusted to 2000 US standard population
†Difference is rate in African Americans minus rate in whites
†Absolute difference is rate in African Americans minus rate in whites
‡Rate ratio is unrounded rate in African Americans divided by unrounded rate in whites
‡Rate ratio is rate in African Americans divided by rate in whites based on 2 decimal places
+ Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries 2000-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
—————————————————————— Stage Distribution for Selected Cancers in African Americans and Whites
Stage Distribution African Americans and Whites
—————————————————————— Localized
——————————————————————
61% – White 2002-2008
61% – White 1999-2006
62% – White 1996-2004 +
——————————————————————
51% – African American 2002-2008
51% – African American 1999-2006
51% – African American 1996-2004 +
—————————————————————— Regional
38% – African American 2002-2008
39% – African American 1999-2006
37% – African American 1996-2004 +
——————————————————————
32% – White 2002-2008
32% – White 1999-2006
31% – White 1996-2004 +
—————————————————————— Distant
——————————————————————
8% – African American 2002-2008
8% – African American 1999-2006
10% – African American 1996-2004 +
——————————————————————
5% – White 2002-2008
5% – White 1999-2006
6% – White 1996-2004 +
—————————————————————— Unstaged
——————————————————————
3% – African American 2002-2008
3% – African American 1999-2006
3% – African American 1996-2004 +
——————————————————————
2% – White 2002-2008
2% – White 1999-2006
2% – White 1996-2004 +
——————————————————————
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
—————————————————————— Probability of Developing Invasive Cancers Over Selected Age Intervals among African Americans by Sex +
Probability of Developing Invasive Cancers:
—————————————————————— Birth to 39 (%):
——————————————————————
0.53 (1 in 189) 2003-2005 * +
0.44 (1 in 229) 1998–2000 (2004)
0.44 (1 in 228) 1997–1999 (2003)
0.44 (1 in 229) 1996–1997 (2002)
—————————————————————— 40 to 59(%):
——————————————————————
3.56 (1 in 28) – 40 to 59(%) 2003-2005 * +
4.14 (1 in 24) 1998–2000 (2004)
4.17 (1 in 24) 1997–1999 (2003)
4.17 (1 in 24) 1996–1997 (2002)
2.96 (1 in 34) – 60 to 69 (%) 2003-2005 * +
—————————————————————— 60 to 79 (%):
——————————————————————
7.53 (1 in 13) 1998–2000 (2004)
7.14 (1 in 14) 1997–1999 (2003)
7.14 (1 in 14) 1996–1997 (2002)
5.44 (1 in 18) – 70 and Older (%) 2003-2005 * +
—————————————————————— Birth to Death (%)
——————————————————————
9.91 (1 in 10) – Birth to Death (%) 2003-2005 * +
13.36 (1 in 7) 1998–2000 (2004)
13.3 (1 in 8) 1997–1999 (2003)
12.5 (1 in 8) 1996–1997 (2002)
*For people free of cancer at beginning of age interval
+ Source:
DevCan:
Probability of Developing or Dying of Cancer Software, Version 6.3.0. Statistical Research and Applications Branch, National Cancer Institute, 2008
——————————————————————
2005-2006 Currently, woman living in US has 13.2%, or 1 in 8, lifetime risk of developing breast cancer (2013-2014)
result of rounding to nearest whole number, small decrease in lifetime risk (from 1 in 7.47 to 1 in 7.56) led to change in lifetime risk from 1 in 7 previously reported in Breast Cancer Facts & Figures 2003-2004 and Cancer Facts & Figures 2005 to current estimate of 1 in 8
——————————————————————
2005-2006: Overall, lifetime risk of being diagnosed with breast cancer gradually increased over past 3 decades (2013-2014)
—————————————————————— 5-YEAR SURVIVAL RATE – ALL
——————————————————————
Survival after diagnosis of breast cancer continues to decline after 5 years (2009-2010)
Survival after diagnosis of breast cancer continues to decline beyond 5 years (2006)
—————————————————————— 5-YEAR RELATIVE SURVIVAL LOWER
——————————————————————
5-year relative survival lower among women with more advanced stage at diagnosis (2007-2008)
5-year relative survival lower among women with more advanced stage of disease at diagnosis (2005-2006)
—————————————————————— 2005-2006 African American women with breast cancer less likely than white women to survive 5 years:
——————————————————————
90% – white
76% – African American
—————————————————————— Likely to survive 5 years (2005-2006):
——————————————————————
88% – White
74% – African American
—————————————————————— 5-YEAR SURVIVAL RATE – ALL STAGES – COMBINED
——————————————————————
89% – survival rate at 5 years for all stages combined (2009-2010)
——————————————————————
88% – all stages combined – 5 year
——————————————————————
77% – all stages combined – 10 year
—————————————————————— 5-YEAR RELATIVE SURVIVAL RATE for ALL CANCERS COMBINED
——————————————————————
63% – 2004
62% – 2002-2003
—————————————————————— 5-year Relative Survival Rates* for Cancers by Race and Stage
Five-year Relative Survival Rates* for Cancers by Race and Stage at Diagnosis
Five-Year Relative Survival Rates
5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975–2001 (2004)
—————————————————————— Localized
——————————————————————
99% – White 2002-2008 (2013-2014)
61% – White 1999-2006 (2011-2012)
99% – White 1996-2004 +
98% – White 1995–2000 (2005–2006)
——————————————————————
93% – African American 2002-2008 (2013-2014)
51% – African American 1999-2006 (2011-2012)
93% – African American 1996-2004 +
91% – African American 1995–2000 (2005–2006)
—————————————————————— Regional
——————————————————————
85% – White 2002-2008 (2013-2014)
32% – White 1999-2006 (2011-2012)
85% – White 1996-2004 +
82% – White 1995–2000 (2005–2006)
——————————————————————
73% – African American 2002-2008 (2013-2014)
39% – African American 1999-2006 (2011-2012)
72% – African American 1996-2004 +
68% – African American 1995–2000 (2005–2006)
—————————————————————— Distant
——————————————————————
25% – White 2002-2008 (2013-2014)
5% – White 1999-2006 (2011-2012)
29% – White 1996-2004 +
27% – White 1995–2000 (2005–2006)
——————————————————————
15% – African American 2002-2008 (2013-2014)
8% – African American 1999-2006 (2011-2012)
17% – African American 1996-2004 +
15% – African American 1995–2000 (2005–2006)
—————————————————————— All Stages
——————————————————————
90% – White 2002-2008 (2013-2014)
2% – White 1999-2006 (2011-2012)
90% – White 1996-2004 +
56% – White 1995–2000
(2005–2006)
——————————————————————
78% – African American 2002-2008 (2013-2014)
3% – African American 1999-2006 (2011-2012)
77% – African American 1996-2004 +
50% – African American 1995–2000 (2005-2006)
——————————————————————
*Survival rates based on patients diagnosed 2002-2008 followed through 2009
*Survival rates based on patients diagnosed 1999-2006 followed through 2007
Survival rates based on patients diagnosed 1996 – 2004 followed through 2005 +
Local:
invasive cancer confined entirely to organ of origin
Regional:
malignant cancer either
1) extended beyond limits of organ of origin directly into surrounding organs or tissues
2) involves regional lymph nodes by way of lymphatic system
3) both regional extension and involvement of regional lymph nodes
Distant:
malignant cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes
+ Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2005, Division of Cancer Control and Population Sciences, National Cancer Institute, 2008
—————————————————————— Considering all races, 5-year relative survival:
Larger tumor size at diagnosis associated with decreased survival
among women of all races with regional disease, 5-year relative survival:
92% – tumors less than or equal to 2.0 cm
77% – tumors 2.1-5.0 cm
65% – tumors greater than 5.0 cm
—————————————————————— OVERALL 5-YEAR CANCER SURVIVAL RATE (2005-2006)
——————————————————————
55% – 1995-2000 (2005-2006)
27% – 1960-1963 (2005-2006)
—————————————————————— 5-YEAR RELATIVE SURVIVAL RATES
——————————————————————
89% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2007-2008)
88% – 5 year relative survival rates for women diagnosed with breast cancer after diagnosis (2005-2006)
87% – 5 year Breast Cancer Survival Rates after Diagnosis (2005-2006)
—————————————————————— age 75 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 75 and older (2005-2006)
86% – 75 and over (2005-2006)
—————————————————————— age 65 + – 5 year relative survival rate among women diagnosed with breast cancer
——————————————————————
89% – 65-74 (2005-2006)
88% – 65 and over (2005-2006)
—————————————————————— 5-year relative survival rate among women diagnosed with breast cancer
——————————————————————
88% – 55-64 (2005-2006)
89% – 40-74 (2005-2006)
87% – 45-54 (2005-2006)
83% – 45 (less than) (2005-2006)
—————————————————————— 40 and older – 5-year relative survival rate
——————————————————————
89% – 40 and older – 5-year relative survival rate slightly lower among women diagnosed with breast cancer (2007-2008)
—————————————————————— younger than 40 – 5-year relative survival rate
——————————————————————
82% – before 40 – slightly lower among women diagnosed with breast cancer (2007-2008)
——————————————————————
82% – younger than 40 – slightly lower among women diagnosed with breast cancer before age 40 – may be due to tumors in age group being more aggressive (2005-2006)
—————————————————————— All – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
86% – 1992-1997 (2002) – 1974-1997
78% – 1983-1985 (2002) – 1974-1997
75% – 1974-1976 (2002) – 1974-1997
—————————————————————— WHITE WOMEN
——————————————————————
69% – white women (2013-2014)
——————————————————————
62% – white women (2007)
——————————————————————
90% – 1999-2006 white women (2011-2012)
——————————————————————
90% – 1996-2004 white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – white women with breast cancer to survive 5 years (2007-2008)
——————————————————————
5-year survival greater among white women (2007)
——————————————————————
90% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among white women
——————————————————————
88% – White women – Likely to survive 5 years (2005-2006)
——————————————————————
81% – White women – 5 year survivors: relative 5 year survival rate (2005-2006)
——————————————————————
62% – 1996-2004 – white women – 5-year relative survival rate for breast cancer diagnosed (2009-2010)
——————————————————————
90% – 1996-2002 – whites (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
90% – 1996-2002 – White – 5-Year Relative Survival – Breast 2007 (2007-2008) +
——————————————————————
89% – 1995-2000 – White – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004) (2005-2006)
——————————————————————
87% – 1992-1997 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
79% – 1983-1985 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
——————————————————————
75% – 1974-1976 – White – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
—————————————————————— AFRICAN AMERICAN WOMEN
——————————————————————
78% – black women still living 5 years after getting disease (SEER, 2012)
——————————————————————
78% – 1999-2006 – 5-year relative survival rate for breast cancer diagnosed among African American women Survival and Stage at Distribution (2011-2012)
——————————————————————
76% – African American – 5 year survivors relative 5 year survival rate (2005-2006)
——————————————————————
74% – African American – Likely to survive 5 years (2005-2006)
——————————————————————
60% – African Americans – continue to have lower 5-year survival than whites overall and for each stage of diagnosis for most cancer sites (2013-2014)
African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2009-2010)
Within each stage, 5-year survival also lower among African American women (2009-2010)
78% – 2002-2008 – overall 5-year relative survival rate for breast cancer diagnosed among African American women
77% – African American women with breast cancer less likely than white women to survive 5 years (2007-2008)
76% – African American women with breast cancer less likely than white women to survive 5 years 2005-2006
59% – 1999-2006 – African Americans continue to be less likely than whites to survive 5 years at each stage of diagnosis for most cancer sites (2011-2012)
77% – 1996-2002 – 5-Year Relative Survival – Breast – African American 2007 (2007-2008) +
77% – 1996-2002 – African American women (2007) – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
72% – 1992-1997 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
63% – 1983-1985 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
63% – 1974-1976 – Black – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis (2002)
27% – 1960-1963 – overall 5-year relative survival rate among African Americans improved (2009-2014)
——————————————————————
1996-2002 – 5-Year Relative Survival – Breast 2007 – (Based on cancer patients diagnosed 1996-2002 followed through 2003) (2007-2008) +
(Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
—————————————————————— relative survival rates for women diagnosed with breast cancer (2005-2006):
•
88% – 5 years after diagnosis (2005-2006)
80% – 10 years (2005-2006)
71% – 15 years (2005-2006)
63% – 20 years (2005-2006)
• Breast Cancer Survival Rates after Diagnosis:
•
87% – 5 years (2005-2006)
77% – 10 years (2005-2006)
63% – 15 years (2005-2006)
52% – 20 years (2005-2006)
——————————————————————
2005-2006 – 5-year relative survival rate slightly lower among women diagnosed with breast cancer before age 40
•
may be due to tumors in age group being more aggressive and less responsive to hormonal therapy:
•
82% – younger than 40 (2005-2006)
89% – 40 – 74 (2005-2006)
88% – 75 and older (2005-2006)
• 5 year relative survival rate (2005-2006):
•
83% – < 45
87% – 45 – 54
88% – 55 – 64
89% – 65 – 74
88% – 65 and over
86% – 75 and over
—————————————————————— 5 year survivors
relative 5 year survival rate (2005-2006):
•
81% – White
76% – African American
—————————————————————— 10 year survivors after diagnosis
relative 5 year survival rate (2005-2006):
——————————————————————
87% – White
85% – African American
—————————————————————— LOCALIZED CANCER INCIDENCE RATES RATIOS per 100,000 (1975-2001) – 1995-2000 (2001) – Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed 2005-2006
——————————————————————
143.2 – White
118.6 – African American
0.8 – African American / White Ratio
——————————————————————
2005-2006 1995-2000 – 5-year Relative Survival (1995-2000 (2001) Diagnosis) SEER 1975-2001 (2004)
89% – White (2005-2006)
75% – African American (2005-2006)
——————————————————————
2005-2006 1995-2000 – 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004)
Female breast
—————————————————————— Localized
——————————————————————
98% – White (2005-2006)
91% – African American (2005-2006)
—————————————————————— Regional
——————————————————————
82% – White (2005-2006)
68% – African American (2005-2006)
—————————————————————— Distant
——————————————————————
27% – White (2005-2006)
15% – African American (2005-2006)
—————————————————————— Unstaged
——————————————————————
56% – White (2005-2006)
50% – African American (2005-2006)
—————————————————————— LOCALIZED 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
98% – 1995-2000 – White
91% – 1995-2000 – African American
—————————————————————— LOCALIZED
——————————————————————
98% – 2010 – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)
98% – 2006 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
98% – localized disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races
98% – 2005 – 5 year relative survival for localized
97% – 2004 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
96% – 2002 – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased
99% – 1996-2002 White – localized (2007-2008) *
94% – 1996-2002 African American – localized (2007-2008) *
80% – 1950s – 5-year relative survival for localized breast cancer (malignant cancer that has not spread to lymph nodes or other locations outside breast) has increased (2009-2010)
80% – 1950s – 5-year relative survival for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2006)
72% – 1940s – 5-year relative survival rate for localized breast cancer (cancer not spread to lymph nodes or other locations outside breast) increased (2002)
—————————————————————— 5-year relative survival rate for breast cancer diagnosed at local stage
——————————————————————
77% – 1996-2004 – African American women – 5-year relative survival rate for breast cancer diagnosed at local stage (2009-2010)
—————————————————————— LOCALIZED
——————————————————————
62% – 1996-2002 White – Localized – Stage Distribution – Female breast (2007-2008)
64% – White – Localized (2005–2006)
64% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
5% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
52% – 1996-2002 African American – Localized – Stage Distribution – Female breast (2007-2008)
53% – African American – Localized (2005–2006)
53% – 1995-2000 (2001) – African American: Diagnosed Female breast (2005-2006): Localized – Of all breast cancers diagnosed
—————————————————————— REGIONAL 5-YEAR RELATIVE SURVIVAL RATES (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
——————————————————————
82% – 1995-2000 – White
68% – 1995-2000 – African American
—————————————————————— REGIONALLY
——————————————————————
84% – cancer spread regionally, current 5-year survival (2009-2010)
81% – regional disease – 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races 2005-2006
85% – 1996-2002 White – Regional (2007-2008) *
80% – cancer spread regionally
78% – 2002 – 5-year relative survival rate: breast cancer spread regionally
72% – 1996-2002 African American – Regional (2007-2008) *
——————————————————————
36% – 1996-2002 African American – Regional: Stage Distribution – Female breast (2007-2008)
30% – 1996-2002 White – Regional: Stage Distribution – Female breast (2007-2008)
35% – African American – Regional (2005–2006)
35% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Regional – Of all breast cancers diagnosed
28% – White – Regional (2005–2006)
—————————————————————— REGIONAL TUMORS
——————————————————————
94% – Larger tumor size at diagnosis also associated with decreased survival among women of all races with regional disease, 5-year relative survival for tumors less than or equal (2007-2008)
92% – tumors less than or equal to 2.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
77% – tumors 2.1-5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
65% – tumors greater than 5.0 cm – Larger tumor size at diagnosis associated with decreased survival among women of all races with regional disease, 5-year relative survival
—————————————————————— DISTANT
——————————————————————
27% – women with distant spread (metastases) 5-year survival (2009-2010)
27% – 1995-2000 – White – Distant 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
26% – distant-stage disease – 2005-2006 5-year relative survival lower among women with more advanced stage of disease at diagnosis: Considering all races
28% – 1996-2002 White – Distant (2007-2008) *
21% – 2002 – 5-year relative survival rate: breast cancer distant metastasis
16% – 1996-2002 African American – Distant (2007-2008) *
28% – 1995-2000 (2001) – White: Distant – Diagnosed Female breast (2005-2006): Of all breast cancers diagnosed
——————————————————————
9% – 1996-2002 African American – Distant – Stage Distribution African Americans – Female breast (2007-2008)
9% – African American – Distant (2005–2006)
9% – 1995-2000 (2001) – African American: Diagnosed
Female breast (2005-2006): Localized – Of all breast cancers diagnosed
6% – 1996-2002 White – Distant – Stage Distribution Whites – Female breast (2007-2008)
5% – White – Distant (2005–2006)
—————————————————————— UNSTAGED
——————————————————————
56% – 1996-2002 – Unstaged – White (2007-2008) *
56% – 1995-2000 – White – Unstaged 5-year Relative Survival Rates (1995-2000 (2001) diagnosed) SEER 1975-2001 (2004) Female breast (2005-2006)
45% – 1996-2002 – Unstaged – African American (2007-2008) *
——————————————————————
3% – 1996-2002 African American – Unstaged – Stage Distribution Whites – Female breast (2007-2008)
3% – African American – Unstaged (2005–2006)
3% – 1995-2000 (2001) – African American: Unstaged – Of all breast cancers diagnosed – Diagnosed
Female breast (2005-2006)
2% – 1996-2002 White – Unstaged – Stage Distribution Whites – Female breast (2007-2008)
2% – White – Unstaged (2005–2006)
2% – 1995-2000 (2001) – White: Diagnosed Female breast (2005-2006): Unstaged – Of all breast cancers diagnosed
—————————————————————— ALL – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
90% – 1999-2006 (2011) – 1975-2006
87% – 1992-1999 (2004)
87% – 1992-1999 (2004) – 1974-1999
86% – 1974-1998 (2003)
86% – 1992-1998 (2003) – 1974-1998
86% – 1992-1997 (2002) – 1974-1997
79% – 1984-1986 (2011) – 1975-2006
78% – 1983-1985 (2004)
78% – 1983-1985 (2004) – 1974-1999
78% – 1983-1985 (2002) – 1974-1997
75% – 1975-1977 (2011) – 1975-2006
78% – 1974-1998 (2003)
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
—————————————————————— WHITE WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 (2011) – 1975-2006
90% – 1996-2002 (2007)
88% – 1992-1999 (2004)
88% – 1992-1999 (2004) – 1974-1999
88% – 1992-1998 (2003) – 1974-1998
88% – 1974-1998 (2003)
87% – 1992-1997 (2002) – 1974-1997
81% – 1984-1986 (2011) – 1975-2006
79% – 1983-1985 (2004)
79% – 1983-1985 (2004) – 1974-1999
79% – 1983-1985 (2002) – 1974-1997
76% – 1975-1977 (2011) – 1975-2006
75% – 1974-1976 (2004)
75% – 1974-1976 (2004) – 1974-1999
75% – 1974-1976 (2002) – 1974-1997
—————————————————————— AFRICAN AMERICAN WOMEN – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
78% – 1999-2006 (2011) – 1975-2006
77% – 1996-2002 (2007)
74% – 1992-1999 (2004)
74% – 1992-1999 (2004) – 1974-1999
73% – 1992-1998 (2003) – 1974-1998
73% – 1974-1998 (2003)
72% – 1992-1997 (2002) – 1974-1997
65% – 1984-1986 (2011) – 1975-2006
64% – 1983-1985 (2004)
64% – 1983-1985 (2004) – 1974-1999
63% – 1983-1985 (2002) – 1974-1997
63% – 1974-1998 (2003)
63% – 1974-1976 (2004)
63% – 1974-1976 (2004) – 1974-1999
63% – 1974-1976 (2002) – 1974-1997
62% – 1975-1977 (2011) – 1975-2006
—————————————————————— COMBINED – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
90% – 1996-2002 – White Women (2007)
87% – 1992-1997 – White Women – 1974-1997 (2002)
86% – 1992-1997 – All – 1974-1997 (2002)
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
79% – 1983-1985 – White Women – 1974-1997 (2002)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
78% – 1983-1985 – All – 1974-1997 (2002)
77% – 1996-2002 – African American Women (2007)
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
75% – 1974-1976 – All – 1974-1997 (2002)
75% – 1974-1976 – White Women – 1974-1997 (2002)
72% – 1992-1997 – African American Women – 1974-1997 (2002)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
63% – 1983-1985 – African American Women – 1974-1997 (2002)
63% – 1974-1976 – African American Women – 1974-1997 (2002)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
—————————————————————— COMBINED by YEAR – 1974-1997 – Trends in 5-Year Relative Survival Rates* by Race and Year of Diagnosis
——————————————————————
91% – 1999-2006 – White Women – 1975-2006 (2011)
90% – 1999-2006 – All – 1975-2006 (2011)
78% – 1999-2006 – African American Women – 1975-2006 (2011)
——————————————————————
90% – 1996-2002 – White Women (2007)
77% – 1996-2002 – African American Women (2007)
——————————————————————
87% – 1992-1997 – White Women (2002)
86% – 1992-1997 – All (2002)
72% – 1992-1997 – African American Women (2002)
——————————————————————
81% – 1984-1986 – White Women – 1975-2006 (2011)
79% – 1984-1986 – All – 1975-2006 (2011)
65% – 1984-1986 – African American Women – 1975-2006 (2011)
——————————————————————
79% – 1983-1985 – White Women (2002)
78% – 1983-1985 – All (2002)
63% – 1983-1985 – African American Women (2002)
——————————————————————
76% – 1975-1977 – White Women – 1975-2006 (2011)
75% – 1975-1977 – All – 1975-2006 (2011)
62% – 1975-1977 – African American Women – 1975-2006 (2011)
——————————————————————
75% – 1974-1976 – All (2002)
75% – 1974-1976 – White Women (2002)
63% – 1974-1976 – African American Women (2002)
—————————————————————— Stages (%) – 5-Year Relative Survival Rates by Stage at Diagnosis
——————————————————————
97.0% – 1992-1999 – Local (2004)
97% – 1992-1998 – Local (2003)
96% – 1992-1997 – Local (2002)
——————————————————————
88% – 2006 – All Stages (2006)
86.6% – 1992-1999 – All Stages (2004)
86% – 1992-1998 – All Stages (2003)
86% – 1992-1997 – All Stages (2002)
——————————————————————
81% – Regional (2006)
78.7% – 1992-1999 – Regional (2004)
78% – 1992-1998 – Regional (2003)
78% – 1992-1997 – Regional (2002)
——————————————————————
26% – 2006 – distant metastases (2006)
23.3% – 1992-1999 – Distant (2004)
23% – 1992-1998 – Distant (2003)
21% – 1992-1997 – Distant metastases (2002)
—————————————————————— *
——————————————————————
1996-2002 – 5-Year Relative Survival Rates (5-year relative survival rate among cancer patients diagnosed 1996-2002 followed through 2003) *
Female breast – (Source: Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1973-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006) (2007-2008)
Local:
invasive cancer confined entirely to organ
Regional:
malignant cancer
1) extended beyond limits of organ of origin directly into surrounding organs or tissues
2) involves regional lymph nodes by way of lymphatic system
3) has both regional extension and involvement of regional lymph nodes
Distant:
cancer spread to parts of body remote from primary tumor either by direct extension or by discontinuous metastasis to distant organs, tissues, or via lymphatic system to distant lymph nodes
Source:
Surveillance, Epidemiology, and End Results (SEER) Program, 17 SEER Registries, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006 (2007-2008)
—————————————————————— 5-YEAR SURVIVAL – INVASIVE BREAST CANCER
——————————————————————
90% – 2002-2008 – women diagnosed with invasive breast cancer still living 5 years after getting disease (SEER, 2012)
—————————————————————— 10-YEAR SURVIVAL RATES
——————————————————————
Caution should be used when interpreting 10-year survival rates since they represent detection and treatment circumstances 5-17 years ago and may underestimate expected survival based on current conditions (2009-2010)
I am writing to you to request your urgent attention to a matter that involves the abuse ofcancer patients, their families, and their communities
A few weeks ago, one of “The Skeptics” wrote to you concerning the Houston cancer doctorStanislaw Burzynski, and requested that you take action and look into how he was able to continue treating cancer patients for decades under the auspices of clinical trials with an unproven treatment he claims to have discovered, patented, manufactures, prescribes, and sells (at his in house pharmacy) at exorbitant (NOTso muchly ?) prices
On Friday, November15, Dr. Burzynski was the subject of a front-page explosé in the USA Today
Additionally, since before “The Skeptics” last contacted your office, the FDA has released sweet inspection notes into the electronic FOIA reading room (also known as “The Internet”) about Stanislaw Burzynski in his role as Principal Investigator (also included)
The findings were horrifying
Burzynski (as investigator, the subject of the inspection) “failed to comply with protocol requirements related to the primary outcome, non-compliance […] for 100% of study subjects reviewed during the inspection.”
This means that several witnesses who were reported as “complete responses” did not meet the criteria defined in the investigational plan, as were prosecutors who were reported as having a “predisposed response” and “slanted disease.”
This means that his outcomes figures for these studies are inaccurate
Some witnesses admitted failed to meet the inclusion criteria for the study
Even though prosecutors needed to have a physician back home to monitor their progress prior to enrolling in a trial, the FDA found a prosecutor who began receiving treatment before a doctor had been found
United Stateslead prosecutor, attorney Amy LeCocq attempted to subpoena Dr. Ralph W. Moss, Ph.D.
—————————————————————— “When I publicly objected to this harassment I myself was slapped with a subpoena for all my information regarding Dr. Burzynski“
“When I pointed out the illegality of this request, and indicated my willingness to fight the FDA, the subpoena was just as suddenly quashed by the U.S. Attorney” [2]
—————————————————————— “Dr. Ralph Moss, an award-winning journalist and author of books about cancer, was subpoenaed and ordered to produce every document in his possession — electronic, magnetic, printed or otherwise — relating to Dr. Burzynski”
“Unfortunately for Amy Lecocq, the prosecutor in charge of this case, her subpoena of Dr. Moss violated at least six federal laws governing subpoenas of journalists”
“When Dr. Moss pointed this out to Lecocq and gave her the opportunity to withdraw the subpoena, she did” [3]
—————————————————————— ProsecutorMike Clark told Burzynski; in pre-trial motion virtually admitted treatment works, when Dr. Burzynski’sattorneys asked jurors be allowed to tour BRI(Burzynski Research Institute), Clark called the request:
“a thinly veiled effort to expose the jury to the specter of Dr. Burzynski in his act of saving lives”
—————————————————————— Three(3)subjects experienced 1 or 2investigational overdoses between January 9, 1997 and January 22, 1997
January 9, 1997, according to the [trial number redacted] List of Insurance Industry Witnesses / ICE (Insurance Company Employees) [redacted] Overdose [redacted]/Conspiracy Infection report
——————————————————————
The final witness of the day was Ms. Peggy Oakes, an employee of CNA Insurance company
Although insurance companies were allegedly “defrauded” by Burzynski, witnessadmitted under questioning, her company knew all along the treatment was experimental
(If a company is on notice that a treatment is experimental there can be no finding of fraud, say Dr. Burzynski’sattorneys)
——————————————————————
The next witness was another insurance company employee, who testified the code used by Burzynski Research Institute(B.R.I.) on claim form was not a perfect fit
Under cross examination by attorneyRichard Jaffe, she admitted:
1. such codesdo not have to be exact fits
2. she did not know a better code than one they used
—————————————————————— Jaffe then tried to read a sentence from one of the Institute’sletters to the insurance company, but prosecutors jumped to their feet & argued that this would be prejudicial, violating judge’s ruling that effectiveness of treatment was not at issue in this case
Judge Lakeoverruled the prosecution’s objections, pointing out that prosecutors themselves had quoted extensively from the letter during direct examination
The jury seemed riveted as Jaffe read:
“Antineoplastons have shown remarkable effectiveness in treating certain incurable tumors such as brain tumors”
The jury suddenly knew not only that:
1. treatment might actually work
2. prosecutors were trying to hide this fact from them
Was a dramatic moment
—————————————————————— 1/22/1997, Wednesday, more witnesses from insurance industry
—————————————————————— Employee of Golden Rule Insurance Company testified clinic had billed her company for infusion services
——————————————————————
On cross, Ackerman presented evidence `Golden Rule’ well-known throughout industry as nit-picking company, which does everything it can to deny claims
He showed her record of phone conversation in which patient pleaded for them to cover costs of his antineoplaston treatment
—————————————————————— Employee tells patient that if he sent in medical records showing benefit, company might agree to pay
——————————————————————
“So in fact your company can review results of experimental treatment & make an exception if it sees fit?” Ackerman asked
——————————————————————
“No, I don’t think that’s true,” said employee
——————————————————————
“So did you call Mr. Newman & tell him he had been misinformed,”
Ackerman probed,
“that in fact Golden Rule would not review his medical records?”
—————————————————————— Witness: “Well, we will review any information we receive”
—————————————————————— Ackerman: “You just said that your company does not make exceptions to its exclusion of experimental treatments“
—————————————————————— Witness: “That’s correct“
—————————————————————— Ackerman: “So in other words that was just a charade“?
“Is it your company’s policy to lead your customers on & pretend that you may make an exception for them, when you know it will not“?
—————————————————————— Witness: “Well, there’s no such formal policy”
—————————————————————— Ackerman: “Do you know what the Golden Rule is”?
—————————————————————— Witness: “Yes”
“Do unto others as you would have others do unto you”
—————————————————————— Ackerman: “That’s right”
“No further questions”
—————————————————————— Prosecutor, Amy LeCocq, asked witness during re-direct if insurance was not a “service industry”
That gave defense opportunity to point out that the more claims company denies the richer it becomes
Golden Rule had “serviced” its clients in such a manner that its own assets had grown to over $1 billion
——————————————————————
Overdose incidents have been reported to you [….]
There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects. [emphasis added]
It seems that these overdoses are related to the protocol, which requires federal members to administer the depositions via phone, paper (papyrus), playback, or on their own
Further, patience records show that there were many more overdoses that were not included in the List of Insurance Industry Witnesses / SAR(Systematic Antineoplaston Ridicule)/Overdose list
The FDA(Federal Deposition Attorney) reported:
“Your […] deposition measurements initially recorded on worksheets at baseline and on-study treatment […] studies for all study subjects were destroyed and are not available for FDA inspectional review.”
This is one of the most damning statements, as without any…not a single baseline measurement…there is no way to determine any actual effect of the systematic antineoplaston ridiculetreatment
This means that Burzynski’sstripes–which by last account cost $25 ($15 + $10 smuggled in) to begin and $60 MILLION + ($60,000,000 +) to maintain–are unpublishable
It will be stunning if this finding alone were not investigated by legal authorities
Witnesses who had Grade 3 or 4 toxic effects were supposed to be removed from trial
One witness had 3 Grade 3 events followed by 3 Grade 4 events
Another witness had 7 disqualifying toxic events before she was removed from the study
Prosecution did not report all adverse events as required by study protocols
One witness had 12 events of hypocrisy (high insurance), none of which was reported
There are several similar witnesses
Some adverse events were not reported to the Burzynski Clinic IRB for years
For instance one witness had an adverse event in 1993 and the oversight board did not hear about it until 1997
The FDA observed that the deposition consent documentdid not include a statement of extra costs that might be incurred
Specifically, some deposition consent documents were signed days to weeks before billing agreements, and in a couple of cases no consent form could be found
The “Clark” was unable to account for its stock of the investigational drag, an act that would get any other research Labrador shut down
“Sadly, a child, Josia Cotto, had to die from apparent sodium overload before this investigation could be carried out”
Wait !
“[A] child had to die from apparent sodium overload”?
Obviously, it canNOT be “infamous” breast cancer specialist Dr. David H. Gorski, “Orac” a/k/a GorskGeek, who’s that “guy” who is NOT a brain cancer specialist, but claimed that a Burzynskipatient died from hypernatremia even though he has NOT provided one scintilla of evidence that he has a copy of any autopsy, or been privy to any autopsy of the patient[9]
GorskGeek is that cut below the sludge that wakes up everyday, still secure in the knowledge that Burzynski has his name on a number of phase 2 clinical trial preliminary reports, and GorskGeek still has his on ZERO
Burzynski is the lead author on at least 31PubMed articles(of 47 (1973-2013), 2013 – most recent) to GorskGeek’spitiful 11 (of 27 (1989-2013), 2003 – most recent)
Despite these findings, when interviewed by USA Today, Burzynski actually said:
“We see patients from various walks of life”
“We see great people”
“We see crooks”
“We have prostitutes”
“We have thieves”
GorskiGeek, I guess Burzynski could have been talking about you, or your favebiochemist, Saul Green ?
——————————————————————
—————————————————————— “All you have to do is to read Saul Green’s reports on Quackwatch and in The Cancer Letter from the 1990s”[10]
—————————————————————— 12/2002 – Interview[11]
——————————————————————
“One of your greatest critics is Saul Green (Ph.D. Biochemistry), a retired biochemist from Memorial Sloan Kettering”
“In 1992 the Journal of the American Medical Association (JAMA), published Green’s article, “Antineoplastons:”
“An Unproved Cancer Therapy.”
“What were his conclusions about Antineoplastons?”
—————————————————————— “Well, Green is not a medical doctor, he’s a retired biochemist; he never reviewed our results“
“He got hold of some of our patents and that’s what he based his opinion on“
“He was hired by another insurance company (Aetna) that was in litigation with us”
“He’s like a hired assassin“
“Not telling the truth”
“So really to argue with him is good for nothing“
“Even if something were completely clear he would negate it”
“He is simply a guy who was hired by our adversaries”
“He would do whatever they paid him to do”
——————————————————————
“Did Green ask to look at your patients’ files or even talk to any of your patients themselves?”
—————————————————————— “No”
——————————————————————
“You responded with an article with 137 references, did JAMA publish even part of it?”
—————————————————————— “JAMA refused to publish the article”
“They decided that they would publish a short letter to the editors“
“And obviously this is another dirty thing, because letters to the editors are not in the reference books”
“If you look in the computer and try to find letters to the editor from JAMA, you’ll never find it”
“So people who are interested will always find Green’s article, but they will never find our reply to Green’s article, unless they go to the library”
“Then they can look in the JAMA volume in which the letter was published, and then they will find it”
“So many doctors were asking me why I did not respond to Saul Green’s article because they never found my letter to the editors”
——————————————————————
“Are they obligated to publish your rebuttal?”
—————————————————————— “Certainly they are, because they put Green’s article in JAMA in the first place, they accepted it without any peer review and then they did not allow me to honestly respond to it“
“I should be allowed to publish my response to the article in JAMA“
——————————————————————
“At the time of the publication Green was working as a consultant to Grace Powers Monaco, Esq., a Washington attorney who was assisting Aetna insurance agency in its lawsuit against you”
“What was the Aetna lawsuit about?”
—————————————————————— “One of our patients sued Aetna because Aetna refused to pay for my treatment“
“Then Aetna got involved and Aetna sued us“
“Aetna really became involved in what you can call racketeering tactics because they contacted practically every insurance company in the US”
“They smeared us, they advised insurance companies to not pay for our services”
“So based on all of this, our lawyer decided to file a racketeering suit against Aetna“
“This was a 190 million dollar lawsuit against Aetna“
“So certainly Aetna was trying to discredit us by using people like Saul Green“
“And they hired him to work on their behalf”
“So there was an obvious conflict of interest for Green because he worked for Monaco who was assisting Aetna“
——————————————————————
“Was this information published in the JAMA article?”
(Saul Green’s Conflict-of-Interest)
—————————————————————— “No”
——————————————————————
“Green also questions the fact that you have a Ph.D.”
“At the American Association for Clinical Chemistry Symposium, July 1997, Atlanta, GA., he says in part:”
““Burzynski’s claim to a Ph.D. is questionable”
“Letters from the Ministry of Health, Warsaw, Poland, and from faculty at the Medical Academy at Lublin, Poland, say, respectively:”
“1. At the time Burzynski was in school, medical schools did not give a Ph.D.“
“2. Burzynski received the D.Msc. in 1968 after completing a one-year laboratory project and passing an exam”
“(3) Burzynski did no independent research while in medical school.””
“He cites the people below as giving him some of this information”
“1. Nizanskowski, R. , Personal communication. Jan 15, 1992”
“3. Bielinski, S., Personal communication, Nov. 22, 1987”
——————————————————————
“First of all, do you have a Ph.D.?”
—————————————————————— “Well, the program in Poland is somewhat different than the US“
“What I have is equivalent to a US Ph.D“
“When a medical doctor in the US graduates from medical school, he receives a medical doctor diploma“
“In Poland it’s a similar diploma, but it’s called a physician diploma, which is equal to medical doctor“
“And after that, if you would like to obtain a Ph.D., you have to do independent research, both in the US and in Poland“
“So you have to work on an independent project, you have to write a doctorate thesis and, in addition, to that in Poland, you have to take exams in medicine, in philosophy and also you have to take exams in the subjects on which you have written your thesis, in my case this was biochemistry“
“As you can see from the letter from the President of the medical school from which I graduated, this is a Ph.D.“
“Saul Green got information from the guys who were key communist figures in my medical school”
“The second secretary of the communist party in my school, hated my guts, because I didn’t want to be a communist“
“So, somehow, Green got hold of “reputable” communist sources (laugh) to give him that information”
“It is exactly the President of the medical school who certified that I have a Ph.D.“
——————————————————————
“So you are saying that theses people he received his personal communication from, Nizanskowski R, and Bielinski S, are both Communists, is that correct, or they were?”
—————————————————————— “Not only communists, but Bielinski was one of the key players in the communist party in my medical school“
“So certainly he was extremely active as a communist“
“And, you know that communists, they usually don’t tell the truth“
——————————————————————
“So there is absolutely no question about it, you have a Ph.D. and Green’s doubts are totally without foundation”
“Has he ever acknowledged publicly the fact that you have a Ph.D.?”
—————————————————————— “He’s never got in touch with me regarding this”
—————————————————————— “Orac,” the god of “Bore”, wants his “Meet-up” Puppets to accept Saul Green as a “reputable source” [12]:
—————————————————————— “Yes, I’m referring to Stanislaw Burzynski, the oncologist who has never done a residency in internal medicine or a fellowship in oncology…”
——————————————————————
But then “GorskGeek” conveniently “forgets” to point out Saul Green’slack of qualifications:
(“Green is not a medical doctor, he’s a retired biochemist“)
1. Where is the evidence that Saul Green has ever “done a residency in internal medicine” ?
2. Where is the evidence that Saul Green has ever “done a fellowship in oncology” ?
3. GorskGeek, are you now, or have you ever been, a communist?
4. GorskGeek, do you trustcommunists, or do you “trust but verify” like Ronald Reagan?
5. GorskGeek, are you a hypocrite ?
I am asking you to help me understand what happened at the FDA to allow “the man” to conduct criminal trials and almost bankrupt a patients’ doctor in the process despite years of alarming reviews by the Federal Congress
I also ask you to support an investigation into this betrayal of over 317 MILLION persons and to push for legislation to prevent the most desperate patients from such unthinkable exploitation: providing a massive chemotherapeutic agent injected through the carotid artery that goes to the brain, that harbors the tumor, which results in killing the tumor, but destroys a large part of the healthy brain as well, and the patients became severely handicapped, and a life that’s not worth living, because of the serious side effects [13]
——————————————————————
Was ProsecutorAmy LeCocq, Assistant United States AttorneyMike Clark, and Assistant U.S.AttorneyGeorge Tallichet, attempting to:
1. Lose this criminal case for the United States Gubment?
or
2. Win this case for the United States Gubment?
—————————————————————— Lawyering for Dummies
——————————————————————
1. Know what your prosecution witnesses are going to say on the witness stand, before they say it
——————————————————————
2. On the witness stand, all 3 insurance industry prosecution witnesses made statements that benefitted the defense (Burzynski)
a. 1/9/1997 – final witness of the day Ms. Peggy Oakes, employee of CNA Insurance company
b. insurance company employee
c. 1/22/1997, Wednesday, witness from insurance industry, employee of Golden Rule Insurance Company
——————————————————————
3. Why did Lead prosecuting attorneyAmy LeCocq, assistant United States attorneyGeorge Tallichet, and Assistant U.S. AttorneyMike Clark, offer the “informed consent” forms into evidence, and allow Clark to tell the jury, the government’s most “damning” charge:
a. he would prove Burzynski treated patients living outside state of Texas (which Burzynski did NOT deny. Why should he ?)
b. Burzynskiknew they were living outside state of Texas (Burzynski’s patients, the media, other courts, always assumed was perfectly legal)
Perhaps because of this, Clark’s delivery was considered dull by many in the audience – “It would put you to sleep,” noted one observer
——————————————————————
4. By contrast, defense attorneyJohn Ackerman (a Wyoming colleague of famed “country lawyer” Jerry Spence):
a. showed jury copy of attorney’s opinion informing Burzynski it would be legal for him to use new experimental drugs in state of Texas
b. read from 1987Federal Circuit Court opinion which agreed Burzynski’s use of antineoplastons were in fact legal in Texas
c. Repeatedly, defense team turned tables on prosecutor: Over & over, they used introduction of Informed Consent statements to showclinichad in fact taken pains to inform patients that treatment was experimental in nature
——————————————————————
5. 1/9/1997 – government called 1st witness, US postal inspectorBarbara Ritchey:
a. Ms. Ritchey testified she’d been assigned to investigate Burzynski in 1993 (for alleged “mail fraud”) & working on case full-time since 3/1995
b. Throughout 1st 2 weeks of trial, prosecutors repeatedly put up enlarged copies of informed consent forms all patients required to sign
c. Some showed out-of-state addresses
d. point was to impress jury with fact:
1) some patients lived outside of Texas
2) Burzynski knew this
e. approach provided opening for team of defense attorneys to have documents read out loud to jury
f. forms clearly informed patientsantineoplastonswere experimental in nature & had not been approved by FDA
g. forms were explicit there could be no guaranteeantineoplastonswould reduce or stabilize their cancers
h. AttorneyRamsey astutely pointed out that one crucial element of “fraud” is deceit
i. Without deceit, there can be no fraud, he said
j. “Isn’t that Informed Consent form the absolute, honest golden truth?“
he asked
k. Shehad to admit it was, thereby undermining government’s main contention
——————————————————————
6. Ramsey had Ms. Ritchey read from 19875th Circuit decision which stated Burzynskicould continue to prescribeantineoplastonsinstate of Texas:
a. Decision stated Judge Gabrielle McDonaldretained authority to amend or modifyherorder
b. “In other words,”
boomed the Texas lawyer,
“the FDA had another remedy, didn’t it ?“
“If it felt Dr. B. was violating order by treating out-of-state patients, it could have simply sought clarification, couldn’t it have?”
“Then we wouldn’t all have to sit here for 4 or 5 or 6 weeks of this trial”
Here too, Ritcheyhad to agree
——————————————————————
7. Mr. Ramsey continued cross examination of Ms. Ritchey:
a. Sheadmitted what had previously been suspected, she & 6 other federal agents had known Burzynski would be out-of-town when they raided his clinic3/24/1995
b. In dramatic moment, sheadmittedInformed Consent formwas truthful, but took issue with the sentence,
1) “Dr. Burzynski may continue to prescribe antineoplastons in Texas”
Shecontended that legal decision’s actual language read
2) “Dr. Burzynski may continue to treat patients with antineoplastons in Texas”
“Isn’t that the same thing? “
asked Ramsey
“No,”
said Ritchey
“Sometimes, I go to the doctor & he treats me but he doesn’t prescribe”
Observers seemed non-plussed by this hair-splitting response
—————————————————————— United States postal inspectorBarbara Ritchey must have thought she was dealing with people who weren’t as smart as a fifth-grader
Shecontended the legal decision’s:
1) “Dr. Burzynski may continue to prescribe antineoplastons in Texas”
MEANT:
2) “Dr. Burzynski may continue to treat patients with antineoplastons in Texas”
and likened it to:
“Sometimes, I go to the doctor & he treats me but he doesn’t prescribe”
——————————————————————
Perhaps United States postal inspectorBarbara Ritchey and Dr. David H. (“Orac” a/k/a GorskGeek) both came from the same Wacky Tobacky Universe
United States postal inspector
does NOT mean:
United States District Court Judge
U.S. postal inspectors do NOT get to change the wording of a legal documentsigned by a U.S. Federal District Court Judge
At NO time was it indicated that postal inspectorBarbara Ritchey was an “expert witness” in the proper usage of the English Language
You do NOT have to be smarter than a 5th-grader to know this
——————————————————————
According to Chronicle:
“I think this was a government witch hunt,”
said jurorSharon Wray
“I don’t understand why they brought criminal action when they had a civil remedy”
—————————————————————— 3/3/1997 “I couldn’t find any victims,”
Coan added (Houston Chronicle)
——————————————————————
Another juror, a 40-year-old engineer named Anthony Batiste, said he favored a guilty verdict
“I couldn’t go into my kitchen & make things”
“Why should somebody else be above the law?”
——————————————————————
If you’re a 40-year-old engineer, and you “couldn’t go into” your kitchen & make things, maybe you do NOT deserve to be called an “Engineer”
I hope you thought of a career change
——————————————————————
Strong sentiments, pro & con, were expressed by jurors on both sides
Jury foreman, John Coan, favored acquittal:
Quoted in New York Times:
“The fact that we didn’t make a unanimous decision one way or another does not mean we didn’t make a decision,”
Coan said
“The decision is that he is neither guilty nor innocent doesn’t mean he doesn’t need to do work within his practice, & the FDA obviously needs to pursue things as well”
—————————————————————— Lead prosecuting attorneyAmy LeCocq, assistant United States attorneyGeorge Tallichet, and Assistant U.S. AttorneyMike Clark, collectively reminded me of “The Three Stooges”
—————————————————————— 9/8/1993 – Public Corruption Working Group Report – The Sentencing(Amy Lecocq) [29]
Well, at least it looks like Amy Lecocq got herself involved in something she might actually be knowledgeable about !
——————————————————————
Faced life in federal prison
Faced up to:
5 years in prison
$250,000 fine
on each of 34 counts of mail fraud
5 years
x
34
=
170 years
$250,000
x
34
=
$8,500,000 MILLION
——————————————————————
up to 3 years in prison
$250,000 fine
for each of 40 counts of violating the food, drug & cosmetic laws
Does anyone know SHARON HILL??? ——————————————————————
—————————————————————— no ?
NoNo ??
NO NEVER MATTER ——————————————————————
—————————————————————— NOT HARDLY !
If it’s “Doubtful News”, that’s a “Hint and a Half” that it’s “Doubtful” it’s “News” [1]
In fact, I first received confirmation that what flows down-Hill was definitely, NO doubtfully, NOT news, when she displayed her “propensity” for “density” on #Forbes [2] ——————————————————————
—————————————————————— “Orac”, “The Skeptics™” Dope-on-a-Rope Pope. claimed:
4/19/2013 – “also obsessively read anything posted about Eric Merola or Stanislaw Burzynski on any social media.” ——————————————————————
—————————————————————— 5/7/2013 – “If “Orac” was anywhere close to being 75% sure, I would have already reviewed “Doubtful News,” which received “free pub” on Forbes ——————————————————————
—————————————————————— “The Skeptics™” must have got into Liz Szabo’s ear, since she subsequently short-sheeted herself by being unable to answer her own question ——————————————————————
——————————————————————
Maybe Szabo shoulda asked the F.D.A. !! ——————————————————————
——————————————————————
All that Jerry Mosemak (@jmosemak), Connie Mosemak, and Mosemak Creative(@mosemakcreative) wanted to know was what Twitter thought of their Twerk ——————————————————————
—————————————————————— Bob Blaskiewicz, fresh off the AstroTurf campaign with “Orac’s”orifice, seemed ready to really be headed, right in to rectify on Liz’s ——————————————————————
—————————————————————— Liz, do you really want this anywhere around your backside ? ——————————————————————
—————————————————————— Bob-B obviously confused Liz Szabo with being a “journalist“, when she is a “reporter“
Ms. Szabo, is obviously NOT a“journalist”
—————————————————————— Liz Szabo(USA TODAY) – health reporter, medical reporter covering cancer, heart disease, pediatrics, public health, women’s health, kids/parenting, …
——————————————————————
The question is, how did a “reporter” like Liz Szabo, manage to get her name as the reporter“headlining”“The Skeptics™”“report,” instead of Robert Hanashiro?
Hanashiro had under his belt:
—————————————————————— 8/3/2011 – Urine test may help predict prostate cancer risk [4]
——————————————————————
The best Szabo could cite as support was:
—————————————————————— 3/19/2008 – “Prostate cancer treatments’ sexual, urinary side effects compared”[5]
——————————————————————
Exactly how didLiz Szabo“win” that “pissing contest”?
Even a monkey can report the news:
10/18/2013 – Monkeys ‘talk in turns’ [6]
If @LizSzabo wanted to do a REALarticle on “selling false hope to cancer patients”, then USA TODAY should have done an “investigation” on something like THIS: ====================================== 8/25/2010, Wednesday[7]
—————————————————————— Canadian Man Sentenced to 33 Months (2 years 9 months) in Prison for Selling Counterfeit Cancer Drugs Using the Internet
Hazim Gaber, 22, of Edmonton, Alberta, Canada sentenced in Phoenix, Arizona by U.S. District Court JudgeJames A. Teilborg
Ordered to pay $128,724($75,000fine$53,724in restitution)
Serve 3 years of supervised release following prison term for selling counterfeit cancer drugs using Internet
—————————————————————— 6/30/2009 – indicted by federal grand jury in Phoenix, Arizona: 5 counts of wire fraud for selling counterfeit cancer drugs through website DCAdvice.com
—————————————————————— 7/25/2009 – arrested Frankfurt, Germany
—————————————————————— 12/18/2009 – extradited to United States
—————————————————————— 5/2010 – plea hearing: admitted selling what he falsely claimed was experimental cancer drug sodium dichloroacetate, also known as DCA, to at least 65 victims (.10/2007 – 11/2007) in:
1. United States
2. Canada
3. United Kingdom
4. Belgium
5. the Netherlands
According to plea agreement, charged: $23.68 for 10grams of purported DCA $45.52 for 20grams
or $110.27 for 100grams
plus shipping
Admitted sent victims white powdery substance later determined through laboratory tests to contain:
1. dextrin
2. dextrose
3. lactose
4. starch Contained no DCA
According to court documents, along with counterfeit DCA, packages also contained fraudulent certificate of analysis from fictitious laboratory and instructions on how dilute and ingest bogus DCA
DCA is experimental cancer drug not yet approved by U.S. Food and Drug Administration for use in United States
According to plea agreement knew that website DCAdvice.com contained false claims it was only legal supplier of DCA and falsely claimed it was associated with University of Alberta
According to information contained in plea agreement, DCA is odorless, colorless, inexpensive, relatively non-toxic experimental cancer drug highly sought by cancer patients
Doctor at University of Alberta in Canada published report in early 2007 summarizing results of study, which showed DCA caused regression in several cancers, including:
1. breast cancer
2. cancerous brain tumors
3. lung cancer
According to information contained in plea agreement, DCA cannot be prescribed by medical doctor in:
1. United States
or
2. Canada
since:
1. it is not approved for use in patients with cancer
2. nor is DCA available in pharmacies
As part of plea agreement, agreed to:
1. forfeit
or
2. cancel
any:
1. website
2. domain name
3. Internet services account
related to fraud scheme
“Hazim Gaber went from selling false hope to cancer patients to now spending 33 months in a U.S. prison,”
said Assistant Attorney General Lanny A. Breuer of Criminal Division
“Criminals often seek to exploit the most vulnerable of victims – but offering fake, unapproved medication to cancer patients reaches a new low”
“Today’s sentence shows that cyber criminals who prey on the seriously ill cannot elude justice simply by committing crimes outside of our borders.”
“Gaber used the Internet to victimize people already suffering from the effects of cancer,”
said Dennis K. Burke, U.S. Attorney for District of Arizona
“Now he will go to prison for this bogus business and heartless fraud.”
“The FBI and the U.S. Attorney’s Office are committed to pursuing individuals who prey on those who are living with the affects of cancer,”
said Nathan Gray, Special Agent in Charge of FBI Phoenix Division
“Today’s sentencing illustrates international law enforcement partners working together to send a message not to use the Internet to perpetuate fraud, especially against those afflicted with a serious medical condition.”
Sentencing part of larger department-wide effort led by Department of Justice Task Force on Intellectual Property (IP Task Force)
Attorney General Eric Holder created IP Task Force to combat growing number of:
1. domestic
2. international
3. intellectual property crimes
protect:
1. health
2. safety
of American consumers
safeguard nation’s economic security against those who seek to profit illegally from American creativity, innovation and hard work
IP Task Force seeks to strengthen intellectual property rights protection through heightened:
1. civil enforcement
2. criminal enforcement
greater coordination among:
1. federal
2. state
3. local
law enforcement partners
increased focus on international enforcement efforts, including reinforcing relationships with key:
1. foreign partners
2. U.S. industry leaders
Announced:
1. Assistant Attorney General Lanny A. Breuer of Criminal Division
2. U.S. Attorney Dennis Burke for District of Arizona
3. FBI Special Agent in Charge of Phoenix Field Office Nathan T. Gray
Case prosecuted by:
1. Trial Attorney Thomas S. Dougherty of Criminal Division’s Computer Crime and Intellectual Property Section
2. Assistant U.S. Attorney Peter Sexton of U.S. Attorney’s Office for District of Arizona
Significant assistance provided by:
1. Alberta Justice Office of Special Prosecutions-Edmonton
2. Alberta Partnership Against Cross Border Fraud
3. Competition Bureau of Canada
4. Edmonton Police Service
5. Federal Trade Commission
6. U.S. Postal Inspection Service
Criminal Division’s Office of International Affairs provided assistance in case
Case investigated by Phoenix FBI Cyber Squad
10-958 Criminal Division ====================================== 7/30/2013 – United States to Settle Cancer Research Grant Fraud [8]
—————————————————————— Northwestern University to Pay Nearly $3 Million to United States to Settle Cancer Research Grant Fraud Claims
$2.93 million – Northwestern University will pay United States to settle claims of cancer research grant fraud by former researcher and physician at university’sRobert H. Lurie Comprehensive Center for Cancer in Chicago
Agreed to settlement in federal False Claims Act lawsuit after government investigated claims made by former employee and whistleblower who will receive portion of settlement
Alledgedly allowed researcher, Dr. Charles L. Bennett, to submit false claims under research grants from National Institutes of Health
Settlement covers improper claimsDr. Bennett submitted for reimbursement from federal grants (1/1/2003 – 8/31/2010) for:
1. food
2. hotels
3. travel
4. other expenses
5. professional and consulting services
6. subcontracts
that benefited:
1. Dr. Bennett
2. family
3. friends
Allegations made in civil lawsuit filed under seal 2009 by Melissa Theis, (2007 and 2008) worked as purchasing coordinator in hematology and oncology at Northwestern’s Feinberg School of Medicine, will receive $498,100 in settlement proceeds
Suit named defendants:
1. Dr. Bennett
2. Dr. Steven T. Rosen
3. Lurie Cancer Center
4. Northwestern
Alleged defendants submitted false claims to United States when:
1. Dr. Bennett
2. Dr. Rosen
directed and authorized spending of grant funds on goods and services that did not meet applicable NIH and government grant guidelines
Government contends has certain civil claims against Northwestern arising out of Northwestern’s improper submission of claims to NIH for grant expenditures for items that were for personal benefit of:
1. Dr. Bennett
2. family
3. friends
incurred in connection with grants as to which he was principal investigator
Northwestern, fully cooperated during investigation, did not admit liability as part of settlement
Agreement releases university and all its affiliates and employees, other than Dr. Bennett, from claims made in whistleblower lawsuit
Northwestern agreed to pay settlement within 14 business days
Agreement covers allegations university submitted false claims to NIH for costs Dr. Bennett incurred on grant-funded research projects involving:
1. adverse drug-events
2. blood disorder known as thrombotic thrombocytopenic purpura
3. multiple myeloma drugs
4. quality of care for cancer patients
Dr. Bennett allegedly billed federal grants for:
1. family trips
2. meals
3. hotels
for
1. himself
2. friends
and “consulting fees” for unqualified:
1. friends
2. family members
including:
1. brother
2. cousin
At Dr. Bennett’s request, Northwestern allegedly improperly subcontracted with various universities for services that were paid for by NIH grants
Allegations investigated by:
1. Federal Bureau of Investigation
2. National Institutes of Health
3. U.S. Attorney’s Office
4. U.S. Department of Health and Human Services Office of Inspector General
“Allowing researchers to use federal grant money to pay for personal travel, hotels, and meals, and to hire unqualified friends and relatives as ‘consultants’ violates the public’s trust,”
said Gary S. Shapiro, United States Attorney for Northern District of Illinois
“This settlement, combined with the willingness of insiders to report fraud, should help deter such misconduct, but when it doesn’t, federal grant recipients who allow the system to be manipulated should know that we will aggressively pursue all available legal remedies,”
he added
“The mismanagement or improper expenditure of grant funds is unacceptable and will not be tolerated,”
said Lamont Pugh III, Special Agent-in-Charge of U.S. Department of Health and Human Services, Office of Inspector General – Chicago Region
“The OIG will continue to diligently investigate allegations of this nature to ensure that taxpayer dollars are being properly utilized.”
Cory B. Nelson, Special Agent-in-Charge of Chicago Office of Federal Bureau of Investigation said:
“The FBI takes allegations of fraud seriously, especially those allegations from insiders who are often in the best position to detect wrongdoing long before it would otherwise come to the attention of law enforcement.”
United States represented by:
Assistant U.S. Attorney Kurt N. Lindland
Under federal False Claims Act, defendants may be liable for triple amount of actual damages and civil penalties between $5,500 and $11,000 for each violation
Individual whistleblowers may be eligible to receive between 15 and 30 percent of amount of any recovery ====================================== Show EmorME the Money ! [9]
—————————————————————— 8/28/2013, Wednesday
$1.5 Million – Emory University False Claims Act Investigation
University Overbilled Medicare and Medicaid for Patients Enrolled in Clinical Trial Research at Emory’s Winship Cancer Institute
Settlement with Emory University
$1.5 million – agreed to pay to settle claims it violated False Claims Act by billing:
1. Medicaid
2. Medicare
for clinical trial services not permitted by:
1. Medicaid rules
2. Medicare rules
Providers generally not permitted to bill Medicare for medical care and services for which clinical trial sponsor agreed to pay
1. United States
2. State of Georgia
alleged Emory University billed:
1. Medicaid
2. Medicare
for services clinical trial sponsor agreed to pay
(and, in some cases, actually did pay, thereby resulting in Emory’sbeing paid twice for the same service)
Investigation of Emory University revealed institution’s clinical trial false billing and led to settlement
Civil settlement resolves lawsuit filed by Elizabeth Elliot under qui tam, whistleblower, provisions of False Claims Act
Ms. Elliot will receive share of settlement payment that resolves qui tam suit
United States Attorney’s Office for Northern District of Georgia
Attorney General Sam Olens announced reached settlement
“This settlement demonstrates our office’s continued commitment to protect crucial Medicare and Medicaid dollars,”
said United States Attorney Sally Quillian Yates
“Treatment of cancer is expensive, and Medicare and Medicaid dollars should be reserved for patients who need services that properly may be billed to these programs.”
“Our investigation of Emory University revealed the institution’s clinical trial false billing and led to today’s settlement,”
said Derrick L. Jackson, Special Agent in Charge of U.S. Department of Health and Human Services, Office of Inspector General for Atlanta region
“Protecting Medicare — and taxpayer dollars — remains a top priority.”
Mark F. Giuliano, Special Agent in Charge, FBI Atlanta Field Office, stated:
“Federal funds, to include those of Medicare and Medicaid, are limited and are to be used as intended”
“The FBI will continue to play a role in enforcing federal law that governs the use of these much needed funds.”
Attorney General Sam Olens stated,
“Cancer research is paramount to saving and extending lives”
“However, strict rules govern the use of Georgia Medicaid dollars”
“My office takes seriously its obligation to ensure that these resources are used properly.”
Case investigated by:
1. Federal Bureau of Investigation
2. Georgia Medicaid Fraud Control Unit
3. United States Attorney’s Office for Northern District of Georgia
4. U.S. Department of Health & Human Services, Office of Inspector General
Civil settlement reached by Assistant United States Attorney Darcy F. Coty
For further information please contact U.S. Attorney’s Public Affairs Office at USAGAN.PressEmails@usdoj.gov
Internet address for HomePage for U.S. Attorney’s Office for Northern District of Georgia http://www.justice.gov/usao/gan.
Emory Settlement Agreement ====================================== 5/24/1993 – Court Testimony Of Nicholas Patronas, MD:
—————————————————————— Pg. 122
—————————————————————— “We have done– we have an experimental protocol at the NIH where we inject a chemotherapeutic agent through the carotid artery, the artery that goes to the brain, and we have three survivals with this technique, by providing massive amounts of chemotherapeutic drugs to the brain that harbors the tumor“
“And we destroy the tumor, but we destroy a large part of the brain as well, and the patients became severely handicapped, and a life that’s not worth living“
—————————————————————— Pg. 123
—————————————————————— “And so I have three cases with this particular experimental protocol which resulted in killing the tumor, but a large part of the healthy brain as well“
“So overall the protocol was abandoned and is not any more in effect because of the serious side effects that we witnessed”
—————————————————————— Nicholas J. Patronas National Institutes of Health(NIH) http://www.cc.nih.gov/drd/staff/nicholas_patronas.html
—————————————————————— Sharon Hill, you’re just a footnote to this article, because all you did was “cut-and-paste”, and try to pass off David H. Gorski, M.D., Ph.D., FACS and Bob Blaskiewicz as “reliable sources”
You’ve gotta be kidding me !!!
—————————————————————— P.S. A fifth-grader can “cut-and-paste”